Urinary incontinence in relationship with anxiety and depression in women : An epidemiological study. by Felde, Gunhild
Gunhild Felde
Urinary incontinence in
relationship with anxiety and
depression in women. 
An epidemiological study. 
2020
Thesis for the degree of Philosophiae Doctor (PhD)
University of Bergen, Norway
at the University of Bergen
Avhandling for graden philosophiae doctor (ph.d )
ved Universitetet i ergen
.
2017
Dato for disputas: 1111
Urinary incontinence in relationship 
with anxiety and depression in women. 
An epidemiological study. 
Gunhild Felde
Thesis for the de ree of P il i  Doctor (PhD)
Date of defense: 09.10.2020
The material in this publication is covered by the provisions of the Copyright Act.
Print:     Skipnes Kommunikasjon / University of Bergen
© Copyright Gunhild Felde
Name:        Gunhild Felde
Title: Urinary incontinence in relationship with anxiety and depression in women. 








1. Scientific environment ........................................................................................................... 4 
2. Acknowledgements ................................................................................................................ 5 
3. Abbrevations .......................................................................................................................... 7 
4. List of publications................................................................................................................. 8 
5. Summary ................................................................................................................................ 9 
6. Norwegian summary ............................................................................................................ 12 
7. Introduction ......................................................................................................................... 15 
7.1 Definitions of urinary incontinence .................................................................................... 16 
7.2 Normal bladder anatomy, function and innervation ............................................................ 19 
7.3 Pathophysiology of urinary incontinence and overactive bladder ....................................... 22 
7.3.1 Overactive bladder and urgency UI........................................................................... 22 
7.3.2 Stress urinary incontinence ....................................................................................... 25 
7.4 Urinary incontinence as a health problem .......................................................................... 25 
7.4.1 Sociological aspects of UI ........................................................................................ 26 
7.4.2 Prevalence ................................................................................................................ 26 
7.4.3 Incidence and remission ........................................................................................... 31 
7.4.4 Impact of urinary incontinence on individuals .......................................................... 32 
7.4.5 Treatment of UI........................................................................................................ 33 
7.5 Risk factors for UI ............................................................................................................. 37 
7.5.1 Depression and anxiety associated with UI ............................................................... 40 
7.5.2 Drugs associated with UI .......................................................................................... 44 
7.6 Anxiety and depression. .................................................................................................... 48 
7.6.1 Anxiety .................................................................................................................... 48 
7.6.2 Depression ............................................................................................................... 48 
7.6.3 Neurobiological aspects in anxiety and depression .................................................... 49 
7.7 Possible mechanisms for the associations between UI and depression and anxiety ............. 51 
8. Aims of the study ................................................................................................................. 54 
9. Material and methods .......................................................................................................... 55 
9.1 The Hordaland Health Study (HUSK) ............................................................................... 55 
9.2 The Nord-Trøndelag Health Survey (HUNT) ..................................................................... 56 
9.2.2 The EPINCONT study ............................................................................................. 58 
9.2.3 Classification of UI variables.................................................................................... 58 
9.2.4 Classification of anxiety and depression ................................................................... 60 
3 
 
9.3 The Norwegian prescription data base (NorPD) ................................................................. 61 
9.3.1 Classification of drug use ......................................................................................... 61 
9.3.2 Confounding variables and risk factors adjusted for .................................................. 62 
9.4 Study design and statistics ................................................................................................. 62 
9.5 Ethical approvals ............................................................................................................... 63 
10. Main Results ........................................................................................................................ 64 
10.1 Paper I .......................................................................................................................... 64 
10.2 Paper II ......................................................................................................................... 66 
10.3 Paper III ....................................................................................................................... 70 
11. Discussion ............................................................................................................................. 72 
11.1 Main findings ............................................................................................................... 72 
11.2 Methodological considerations ...................................................................................... 72 
11.2.1 Design...................................................................................................................... 72 
11.2.2 Precision .................................................................................................................. 73 
11.2.3 Validity .................................................................................................................... 74 
11.3 Discussion of the results ............................................................................................... 88 
11.3.1 Anxiety and UI ......................................................................................................... 88 
11.3.2 Depression and UI .................................................................................................... 90 
11.3.3 The impact of psychotropic drugs ............................................................................. 92 
11.3.4 The models of aetiology ........................................................................................... 95 
12. Future perspectives for clinical practice and research ....................................................... 97 
13. Conclusions .......................................................................................................................... 99 
14. References .......................................................................................................................... 101 





1. Scientific environment 
The studies presented in this thesis have been carried out at the Department of Global 
Public Health and Primary Care, the Faculty of Medicine, at the University of 
Bergen. My main supervisor, Steinar Hunskår, is professor of general practice at this 
department. The two first studies were carried out in the period 2008 to 2016, and 
were funded by Norwegian GPs´ Research Fund (Allmennmedisinsk forskningsfond, 
the Norwegian Medical Association). In September 2016, I was admitted as a ph.d. 
fellow, and my work proceeded with funding from The University of Bergen. My 
research on urinary incontinence (UI) follows after the work of several incontinence 
researchers at the Department of Global Public Health and Primary Care. They have 
worked for many years to investigate associations regarding UI in women. A large 
body of knowledge about methodology used in population-based research on UI has 
been consolidated here during the years. The questionnaires used in my studies were 




Many years have passed since I initially knocked on professor Hunskår´s door back 
in 2006, and asked for a research project to take part in. The field of urinary 
incontinence seemed to be an interesting research area and a condition well known to 
me in my general practice with many female patients. I want to express my heartfelt 
thanks to my supervisor Steinar Hunskår for sharing with me some of his tremendous 
experience and expertise as a well-known UI researcher. His professional supervision 
and systematic approach to research problems always make our meetings inspiring 
and constructive. I am grateful for his acceptance of my need for using many years to 
complete this thesis. He always found a way to make it possible for me to combine 
general practice and research. I have also appreciated his experience as a general 
practitioner.   
Professor Anders Engeland has been my co-supervisor in the last part of the project. I 
am very grateful for all his experienced help with NorPD and the medication data, for 
statistical and methodological help, and for giving swift and precise feedback on my 
questions and the manuscripts.  
I want to thank professor Ingvar Bjelland and ph.d. Marit Ebbesen for invaluable help 
with the statistics, to Ingvar for supervision on the use of HADS, and to Marit for 
help with the UI-variables.  
In addition, I thank my colleagues at Department of Global Public Health and 
Primary Care for their inspiring work to evolve the field of general practice and for 
involving me in educating new generations of doctors. I also want to thank for their 
warm generosity, and also their including attitude and wisdom, making the 
environment encouraging and the lunches interesting.  
The Norwegian Research School in General Practice has been an important scene for 
meeting colleagues and exchange ideas, and I especially want to thank professor 
Sabine Ruths for inviting me to the school and associated professor Stefan 
Hjørleifsson for his teaching.   
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I want to thank my good colleagues at my practice Helse Pluss for their patience with 
my research career, and my patients for reminding me what really is important to me 
as a doctor, and for welcoming me back every time I have been in research leave. 
To achieve a ph.d. is not possible without support from many people around. My 
greatest thank to Karstein, my best friend, husband and fantastic father for our 
children. He has supported and encouraged me to complete the thesis, and also 
contributed with good scientific advice and invaluable help with tables, charts, and 
manuscript proofreading. 
I want to thank my mother-in-law, Sissel, for all practical support in daily life and for 
all the good care and love she brings into our home, making the realisation of this 
thesis more feasible.  
I want to thank my parents for their constant support and belief in me from early 
years.  
My greatest gift in life is our beautiful children Dorthea (13), Ellisiv (11) and 
Henning (8). I thank them for just being themselves, and through that filling my life 





“Thankfulness is the eye-drops needed to take every day to see clearly.”             





ATC:   Anatomical Therapeutic Chemical 
BMI:   Body Mass Index 
CI:   Confidence Interval 
DDD:  Defined Daily Dose 
EPINCONT: Epidemiology of Incontinence in the County of Nord-Trøndelag 
HADS:  Hospital Anxiety and Depression Score 
HADS-D:  The depression-part of the HADS questionnaire 
HADS-A:  The anxiety-part of the HADS questionnaire 
HUSK:  The Hordaland Health Study (1997-1999) 
HUNT:  The Nord-Trøndelag Health study 
HUNT1:  The HUNT1 survey (1984-1986) 
HUNT2:  The HUNT2 survey (1995-1997) 
HUNT3:  The HUNT3 survey (2006-2008)  
ICS:   International Continence Society 
ICI:   International Consultation on Incontinence 
NorPD:  Norwegian Prescription Database 
OR:   Odds Ratio 
Q1-Q2:  Questionnaire 1-2 
QoL:   Quality of Life  
SSRI:   Selective Serotonin Reuptake Inhibitor 
SNRI:  Serotonin and Noradrenaline Reuptake Inhibitor 
UI:   Urinary Incontinence 
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5. Summary  
Urinary incontinence (UI) affects a large proportion of women during their lives. 
Pregnancy and parity, obesity and increasing age are regarded as the most important 
and best documented risk factors for UI in women. Many co-morbid conditions are 
associated with increased prevalence of UI, such as diabetes, coronary heart disease, 
cerebral stroke, asthma/COPD, rheumatoid arthritis and chronic musculoskeletal 
pain. Studies have also shown an association between symptoms of anxiety and 
depression and UI. Especially urgency UI and overactive bladder have been 
investigated in relationship with anxiety and depression. The serotonergic and 
noradrenergic system has a place in the pathophysiology in both UI, anxiety, and 
depression, which supports the epidemiological substrate.  
The documented effect of treatment with the serotonin- and noradrenaline reuptake 
inhibitor duloxetine on stress UI, also strengthens the hypothesis of a common 
underlying biological association between the conditions.  
This thesis is an epidemiological study of the associations between anxiety and UI 
and depression and UI in women. The aims of the thesis were: 
- To determine if anxiety and depression is associated with UI in middle-aged 
women, and to investigate a possible association with type and severity of UI. 
- To investigate the association between anxiety/depression and UI in a 10-year 
follow-up study. 
- To determine the association between anxiety/depression and UI in a 
population with women 20 years+, and to investigate if the associations are 
influenced by using psychotropic drugs. 
Our studies are based on data from The Hordaland Health Study (HUSK) (Paper I), 
the Nord-Trøndelag Health Study (HUNT) (Paper II and Paper III) and the 
Norwegian Prescription Database (NorPD) (Paper III). The questions about UI were 




experienced leakage of urine and further questions about type, frequency and amount 
of leakage. The Norwegian version of the questionnaire Hospital Anxiety and 
Depression Scale (HADS) was used in both surveys to measure the level of anxiety 
and depression.  
Paper I 
Paper I is based on data from HUSK. The study population consisted of 5321 
women 40-44 years of age who answered the questionnaire, which contained both the 
HADS- and UI-questions. The prevalence of UI was 26%. Of these, 53% had stress 
UI, 9% urgency UI and 30% mixed UI. We found an association both between 
anxiety and UI, and between depression and UI, strongest for mixed UI, urgency UI 
and severe UI. Of the whole study-population 20% had anxiety and 8% depression, 
among women with mixed UI, 32% had anxiety and 17% depression, and in the 
group with severe UI, 34% had anxiety and 16% depression.  
Paper II 
Paper II was based on data from both HUNT2 and HUNT3. The study population 
consisted of 16.263 women who had answered the questionnaires about UI, anxiety 
and depression in HUNT2 and HUNT3. We wanted to compare the development of 
anxiety and depression over the 10-year follow-up among those who had UI in 
HUNT2 compared with those who were continent in HUNT2. We also wanted to 
compare development of UI among those with anxiety and among those with 
depression in HUNT2, compared with development of UI among those without 
anxiety and depression in HUNT2. We found that anxiety and depression in HUNT2 
was associated with increased risk of development of UI, strongest for the urgency 
component of UI. This association was strongest in the groups with the highest 
HADS-scores. UI in HUNT2 was also associated with increased risk of development 
of anxiety and depression, strongest for mild anxiety/depression.  
Paper III 
Paper III was based on data from the HUNT3 and the NorPD. 21803 women who 
had answered the UI-questions in HUNT3 were linked to NorPD. From the NorPD 
we got information about all prescriptions dispensed for all individuals in the study. 
11 
 
The prevalence of UI was 29% in the total group, 38% in the group with 
moderate/severe anxiety and 44% in the group with moderate/severe depression. 
Mixed UI was the UI type strongest associated with anxiety and depression. The 
prevalence of UI did not increase significantly in the subgroups with 
anxiety/depression using an antidepressant or anxiolytic drug compared with non-
users in the same subgroups. We found increased prevalence of UI among users of 
many psychotropics compared with non-users. After adjustments, however, UI was 
positively associated with the use of antidepressants. We found a weak, negative 
association with use of anxiolytics.  
Our results show that UI is associated with anxiety and depression. Also, anxiety and 
depression are predictors for development of UI in the longitudinal study. The 
association is strongest for severe UI and mixed UI. Use of psychotropic drugs does 





6. Norwegian summary 
Urinlekkasje (urininkontinens) rammer en stor andel av kvinner i løpet av livet. 
Svangerskap og fødsler, fedme og stigende alder er ansett som de viktigste og best 
dokumenterte risikofaktorene for urinlekkasje hos kvinner. Ved en rekke tilstander er 
det påvist økt forekomst av urinlekkasje, slik som ved diabetes, hjerte- og 
karsykdommer, hjerneslag, astma/KOLS, leddgikt og fibromyalgi. Studier har også 
påvist en sammenheng mellom depresjons- og angstsymptomer og urinlekkasje. 
Særlig har hastverkslekkasje (urgency urinlekkasje) og overaktiv blære vært 
undersøkt i relasjon til angst og depresjon. Det serotonerge og noradrenerge systemet 
spiller en rolle i patofysiologien ved både urinlekkasje, angst og depresjon, og dette 
støtter de epidemiologiske funnene. Dokumentert effekt av behandling med 
serotonin- og noradrenalin-reopptakshemmeren duloksetin mot anstrengelseslekkasje 
(stressinkontinens), styrker også hypotesen om en felles underliggende biologisk 
sammenheng mellom tilstandene.  
Denne avhandlingen er en epidemiologisk studie av sammenhenger mellom angst og 
urinlekkasje, og mellom depresjon og urinlekkasje, hos kvinner. Målene med 
avhandlingen var å undersøke: 
- om angst og depresjon er assosiert med urinlekkasje hos middelaldrende 
kvinner, og undersøke en eventuell sammenheng med ulike typer og 
alvorlighetsgrader av urinlekkasje.  
- assosiasjonen mellom angst/depresjon og urinlekkasje i en longitudinell studie 
med ti års oppfølgingstid.  
- om angst og depresjon er assosiert med urinlekkasje i et materiale med kvinner 
over 20 år, og om disse sammenhengene påvirkes av psykofarmakologisk 
medikamentbruk.  
Datamaterialet er hentet fra Helseundersøkelsen i Hordaland (HUSK) (artikkel I), 
Helseundersøkelsen i Nord-Trøndelag (HUNT) (artikkel II og III) og 
Reseptregisteret (NorPD) (artikkel III). Kvinnene ble spurt om de hadde opplevd å 
lekke urin, samt tilleggsspørsmål om lekkasje-type, hvor ofte de opplevde lekkasje, 
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og mengde av lekkasjen. Norsk versjon av spørreskjemaet Hospital anxiety and 
depression scale (HADS) ble brukt i begge helseundersøkelsene for å kartlegge nivå 
av angst og depresjon. 
Artikkel I 
Datamaterialet i artikkel I var hentet fra HUSK. Studiepopulasjonen bestod av 5321 
kvinner mellom 40 og 44 år. De besvarte spørsmål om angst, depresjon og 
urinlekkasje. Forekomsten av urinlekkasje i studiepopulasjonen var 26%, av disse 
hadde 53% anstrengelseslekkasje, 9% hastverkslekkasje og 30% blandingslekkasje. 
Vi fant at både angst og depresjon var assosiert med urinlekkasje, sterkest ved 
blandingslekkasje og hastverkslekkasje, og ved alvorlig urinlekkasje. I hele 
studiepopulasjonen hadde 20% angst og 8% depresjon, hos de med blandingslekkasje 
hadde 32% angst og 17% depresjon, ved alvorlig urinlekkasje hadde 34% angst og 
16% depresjon.   
Artikkel II 
Datamaterialet i artikkel II var hentet fra både HUNT2 og HUNT3. 
Studiepopulasjonen bestod av 16.263 kvinner som hadde besvart spørreskjemaene 
som handlet om urinlekkasje, angst og depresjon både i HUNT2 og HUNT3. Vi ville 
sammenligne utvikling av angst og depresjon i tiårsperioden hos de som hadde 
urinlekkasje i HUNT2 sammenlignet med de som var kontinent i HUNT2. Vi ville 
også undersøke utvikling av urinlekkasje hos kvinner med angst og depresjon i 
HUNT2 sammenlignet med de som ikke hadde disse tilstandene i HUNT2. Vi fant at 
både angst og depresjon i HUNT2 var forbundet med økt risiko for utvikling av 
urinlekkasje, mest for «hast»-komponenten av urinlekkasje. Sammenhengen var 
sterkest i gruppene med høyest HADS-skår. I HUNT2 var urinlekkasje også 
forbundet med økt risiko for utvikling av angst og depresjon, hovedsakelig i mild 
grad. Også her var sammenhengen sterkest i gruppen med hastverkslekkasje.  
Artikkel III 
Datamaterialet i artikkel III var hentet fra HUNT3 og Reseptregisteret. 21.803 
kvinner som besvarte spørsmålene om urinlekkasje i HUNT3 ble koblet til 
Reseptregisteret. Fra Reseptregisteret fikk vi opplysninger om uttak av alle 
14 
 
reseptbelagte legemidler for personene i studien. Forekomsten av urinlekkasje var 
29%, anstrengelseslekkasje var vanligst i de to yngste aldersgruppene (opp til 54 år), 
blandingslekkasje var vanligst i gruppen over 54 år. Forekomsten av urinlekkasje var 
38% i gruppen med moderat/alvorlig angst, og 44% i gruppen med moderat/alvorlig 
depresjon. Blandingslekkasje var også her sterkest assosiert med angst og depresjon. 
Forekomsten av urinlekkasje var ikke signifikant økt i gruppene med depresjon/angst 
som brukte antidepressive eller anxiolytiske medikamenter. I hele studiepopulasjonen 
fant vi høyere forekomst av urinlekkasje blant brukere av mange av de 
psykofarmakologiske medikamentene. Etter at det var kontrollert for 
justeringsvariabler, var urinlekkasje assosiert med bruk av antidepressiva. Vi så en 
svak tendens til at anxiolytiske medisiner var forbundet med litt lavere forekomst av 
urinlekkasje.  
Våre resultater viser at angst og depresjon er forbundet med økt forekomst av 
urinlekkasje, samt utvikling av urinlekkasje over tid. Sammenhengen er sterkest for 
alvorlig urinlekkasje og blandingsinkontinens. Bruk av psykofarmakologiske 






7. Introduction  
UI is a common health problem with a wide range of severities and degrees of 
symptom burden. Incontinence after early childhood is associated with shame and 
taboo. Losing control and wetting oneself in adulthood, especially if unpredictable, 
may seriously affect the physical and psychological well-being and limit social life 
for the affected individuals. In other cultures, the taboo and social consequences can 
be even worse. As a shameful, not life-threatening health problem affecting mostly 
women, it has throughout medical history been a low-status, underdiagnosed health 
problem.  
Epidemiology is the study of the distribution of disease (descriptive epidemiology) 
and the determinants of disease frequency (analytic epidemiology). Epidemiologic 
knowledge is necessary to prevent illness and disease, both on an individual level and 
for the society by giving advice and suggestions to improve public health.  
Epidemiologic research has created knowledge about risk factors and associated 
factors for UI1. Old age, pregnancy, childbirth and high BMI are regarded as the most 
established risk factors for UI2. Several comorbidities are found to be associated with 
UI, such as diabetes, urinary tract infection, cognitive impairment, ischemic heart 
disease and physical impairment. Several studies have also showed an increased 
occurrence of anxiety and depression among women with UI, as well as increased 
occurrence of UI among women with anxiety and depression3. Generally, most 
studies in this field are cross-sectional, and can therefore not contribute to evidence of 
causation. We know that UI has psychological effects and impact on emotional well-
being4. Intuitively, loss of control, unpredictable leakage and social isolation because 
of fear of leaking urine in inappropriate situations, could lead to depressive symptoms 
and anxiety. There are also possible biological common pathways between the 
conditions that could explain an association. The use of certain antidepressant drugs 
for stress UI have contributed to interest of biological mechanisms behind the 
observed coexistence. However, even if some antidepressant drugs have been 
effective in treating stress UI, other studies have showed a positive cross-sectional 
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association between using antidepressants and UI. If, however, there is an association 
between depression and UI, and between anxiety and UI, a logical hypothesis would 
also be that treating those conditions with antidepressants should improve the UI. The 
present work intends to deepen the epidemiological knowledge about the associations 
between anxiety and UI, and depression and UI, in women.   
In this introductory chapter, I will first present the current consensus definitions of 
UI, then give a presentation of the normal function and innervation of the bladder 
followed by an explanation of the pathophysiology in different UI types. 
Furthermore, I will describe several aspects of UI as a health problem, individually 
and societal, and give an overview of established and potential risk factors for UI 
with emphasis on anxiety and depression. Finally in this chapter, I will, based on the 
literature, present possible psychological and biological mechanisms for the 
coexistence of anxiety and UI, and depression and UI.  
7.1 Definitions of urinary incontinence  
The existence of different definitions of UI is a challenge when interpreting 
epidemiological studies of the distribution of UI5. UI can be diagnosed subjectively 
(by self-reported symptoms) or objectively (by clinical signs and investigations). The 
International Continence Society (ICS), is an international society for the study of 
lower urinary tract dysfunction. The first report on the standardisation of terminology 
of lower urinary tract symptoms was presented in 1979. UI was then defined as 
“involuntary loss of urine that is objectively demonstrated and a social and hygienic 
problem”. This definition was rather restrictive, and the objective demonstration of 
UI was not feasible in large population-based epidemiological studies. The 
implementation of social and hygienic aspects in questionnaires, and the 
interpretation of information about such problems was a challenge. It was also 
demonstrated that the prevalence of UI varied widely in the same population 
depending on which definition used6. 
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ICS is a co-organiser of several conferences called International Consultation on 
Incontinence (ICI), and in 1998, the ICI Epidemiology committee, chaired by 
professor Steinar Hunskår, recommended that neither objective demonstration nor 
social or hygienic problems should be included in the definition of UI7. 
From 2002, ICS established a symptom-based definition of UI as the “complaint of 
any involuntary loss of urine”8. This is in accordance with the WHO ICIDH-2 
(International Classification of Impairment, Disability and Health) and the ICD10 
(International Classification of Diseases) 9. The definition is based on symptoms only, 
and lacks spesifications of frequency, amount of leakage or impact on quality of life. 
All ranges of symptoms are included. In the 2002 ICS report on standardisation of 
terminology, there is a sharp distinction between “symptoms” as the subjective 
indicator of UI , “signs” as the physician´s observations to characterise and quantify 
the symptoms, the “urodynamic observation/investigation”, and at last UI as a 
“condition” as the presence of urodynamic observations associated with signs and 
symptoms. The distinction between symptom, sign, investigation and condition 
reflects different research areas and clinical settings.  
This thesis applies the current terminology for female UI, defined by ICS and the 
International Urogynecological Association (IUGA) in 2010 through a joint report on 
the terminology for female pelvic floor dysfunction10. Table 1 shows the symptom-
based terminology of UI and UI types as defined in this report. 
Even if the current definition is only symptom-based, ICS recommends that all 
epidemiological research on UI, in addition to screening questions for any 
involuntary loss of urine, should also include measures of subgroups like type, 
frequency, social impact, quality of life, and whether the woman has seeked help 
because of the UI.  
The most common types of UI are stress, urgency and mixed UI. There are no 
validated questionnaires for the less common types, and therefore also a lack of 
studies bringing knowledge about prevalence and risks2. They are in many studies, 
and also in this thesis, grouped as “other incontinence”. 
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Table 1. Definitions of UI symptoms according ICS/IUGA10 
Type of UI Symptoms 
  
Urinary incontinence Complaint of any involuntary loss of urine 
  
Stress urinary incontinence Complaint of involuntary loss of urine on effort or physical 
exertion (e.g., sporting activities), or on sneezing or coughing 
  
Urgency urinary incontinence Complaint of involuntary loss of urine associated with 
urgency  
  
Mixed urinary incontinence Complaint of involuntary loss of urine associated with 
urgency, and also with effort or physical exertion or on 
sneezing or coughing  
  
Postural urinary incontinence Complaint of involuntary loss of urine associated with change 
of body position, for example, rising from a seated or lying 
position 
  
Nocturnal enuresis Complaint of involuntary loss of urine which occurs during 
sleep 
  
Continuous urinary incontinence Complaint of constant leakage of urine  
  
Insensible urinary incontinence Complaint of urinary incontinence where the woman has 
been unaware of how it occurred  
  
Coital urinary incontinence Complaint of involuntary loss of urine with coitus 
 
Table 2. Definitions of bladder storage symptoms according to ICS/IUGA10  
Type of bladder storage symptom Symptom 
  
Increased daytime urinary frequency Complaint that micturition occurs more frequently during 
waking hours than previously deemed normal by the 
woman 
  
Nocturia Complaint of interruption of sleep one or more times 
because of the need to micturate. Each void is preceded 
and followed by sleep 
  
Urgency Complaint of a sudden, compelling desire to pass urine 
which is difficult to defer 
  
Overactive bladder syndrome  
(OAB, urgency) 
Urinary urgency, usually accompanied by frequency and 
nocturia, with or without urgency urinary incontinence, in 
the absence of urinary tract infection or obvious pathology 
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The ICS/IUGA also defines bladder storage symptoms as displayed in Table 2. 
Urgency UI is regarded part of a larger symptom complex, called overactive bladder 
syndrome, which is characterised by being dry (without leakage) or wet (with 
leakage). 
7.2 Normal bladder anatomy, function and innervation 
The bladder wall is an involuntary controlled muscle (detrusor muscle) consisting of 
three muscle layers. The outer muscular layer runs from the bladder neck to the 
vertex. The middle layer consists of circular muscle fibres. The inner layer is 
longitudinal directed and continues directly into the internal longitudinal muscle of 
the urethra, the internal smooth muscle sphincter in the bladder neck under 
involuntary control, keeping the upper urethra and the bladder closed during the 
storage phase. There is also an external urethral sphincter (rhabdosphincter) of 
striated muscle fibres under voluntary control. In addition to the bladder and urethra, 
the pelvic floor muscles (levator ani muscles) are important in controlling the urine 
flow.  
The control of these muscles involves the central nervous system (CNS), the afferent 
sensory and the efferent somatic and autonomous parts of the peripheral nervous 
system. The innervation of the bladder, urethra and pelvic floor is shown in figure 1.  
The different parts of the innervation and its effects on the bladder and urethra are 
summarised here:    
1. The autonomous innervation, consisting of: 
 the sympathetic hypogastric nerve fibres from T11 to L2: contraction of 
the internal muscle sphincter and increased compliance of the bladder 
detrusor; 
 the parasympathetic pelvic nerve fibers from S2 to S4: contraction of the 
detrusor.  
2. The somatic efferent pudendal nerve (from S2-S4), which provides a 




Figure 1. The innervation of the bladder, urethra and pelvic floor. Illustration by Kari C Toverud. 
 
In the storage phase an increasing bladder volume (up to 400-600 mL) will activate 
stretch receptors in the bladder wall leading to afferent signals transmitted to the 
CNS. These signals result in increased sympathetic activation from the thoraco-
lumbar spinal cord through the hypogastric nerve, which releases noradrenaline (NA) 
peripherally. NA stimulates β3-adrenergic receptors in the detrusor (increased 
compliance) and the α1A-receptors in the urethral smooth muscles (contraction of the 
internal sphincter). During filling of the bladder, there is also an activation of the 
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efferent somatic fibres through the pudendal nerve and release of acethylcholine 
(Ach) acting via the nicotinic receptors peripherally. This leads to contraction of the 
striated external sphincter muscle, which activity can be augmented voluntarily. At 
the same time there is an inhibition of the parasympathetic cells.  
At Onuf´s nucleus in the spinal cord, nerves from higher centres in the CNS synapse 
with the pudendal motor neurons. The neurotransmitter glutamate starts the pudendal 
activity in Onuf´s nucleus. NA and serotonin (5-HT) are neurotransmitters that 
modulate the activity at the proximal end of the pudendal nerve and acetylcholine is 
the transmitter at the distal end of the pudendal nerve. When released, it initiates 
contraction of the rhabdosphincter.  
In the voiding phase an increasing afferent activity from the bladder exceeds a certain 
threshold, and if the higher brain centres find the situation acceptable for voiding, it 
leads to stimulated output from the pontine micturition centre to the parasympathetic 
centre in the spinal cord. This leads to inhibition of efferent activity to the striated 
sphincter (somatic nerves) and the urethra and bladder neck (sympathetic nerves). 
The parasympathetic nerves release acetylcholine in the nerve ends, and this leads to 
detrusor contraction.   
The role of 5-HT in micturition 
5-HT and NA terminals are dense in different parts of the central nervous system. In 
vivo experiments in animals have showed that activity of 5-HT and NA in the CNS 
affects the bladder and urethral function11. Animal experiments also indicate that 
central serotonergic activity suppresses parasympathetic activity (inhibiting voiding) 
and enhance sympathetic and somatic activity (enhance control of urethral outlet). 
There are several subtypes of receptors on which serotonin interacts. 5-HT1, 5-HT2 
and 5-HT3 receptors are present in the lumbosacral spinal cord. 5-HT1A - receptors are 
localised in areas in the dorsal horn with bladder afferent fibres and in the 
parasympathetic nucleus and the Onuf´s nucleus. 5-HT2 receptors are localised in the 
sacral parasympathetic nucleus and Onuf´s nucleus. Stimulation of central 5-HT 
receptors facilitates the storage of urine12, 13. 
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Peripherally, most of the total 5-HT is located in the gastrointestinal tract, but it is 
also present in neurons in the lower urinary tract, and it interacts with many different 
subtypes of 5-HT receptors14 15.  A study in rats indicated that activation of serotonin 
5-HT1A receptors are involved in the pathogenesis of UI16. A possible consequence of 
activation of 5-HT4 receptors of the bladder, is increased detrusor activity, leading to 
UI15. The 5-HT4 receptor can be activated when using a selective serotonin reuptake 
inhibitor (SSRI or SNRI).  
7.3 Pathophysiology of urinary incontinence and overactive 
bladder  
7.3.1 Overactive bladder and urgency UI 
Urgency UI is regarded as part of a larger symptom complex known as overactive 
bladder syndrome, as described in the section about definitions of UI types. There is 
no full agreement about the pathophysiology of urgency and urgency UI. 
Traditionally, the cause has been considered to be overactivity of the detrusor, which 
could be either “myogenic” (autonomous contractions of the detrusor muscle) or 
“neurogenic” (signals from the CNS initiating detrusor contractions). Detrusor 
overactivity is defined as “a urodynamic observation characterised by involuntary 
detrusor contractions during the filling phase which may be spontaneous or 
provoked”. Urodynamic investigations have, however, revealed that only about 50% 
of patients with overactive bladder have detrusor overactivity17, 18, and at least half of 
elderly asymptomatic individuals have detrusor overactivity18. Over the last years, the 
scientific view has shifted in direction that the overactive bladder and urgency often 
is initiated from the urothelium/suburothelium and the urethra through pathological 
afferent signalling. A review article from 2019 summarises the different hypotheses 
for the phenotypes of overactive bladder and urgency17, and they are cited here:  
The myogenic hypothesis 
Urgency originating from a myogenic dysfunction and supersensitivity. Detrusor 
overactivity could be a consequence of histological changes leading to abnormal 
electrical coupling among the smooth muscle cells in the detrusor, causing detrusor 
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contractions. Also, increased afferent signals caused by urothelial/suburothelial 
dysfunction could lead to uninhibited detrusor contractions. Detrusor overactivity 
could also be a consequence of changes in the central nervous control of the 
micturition reflex. 
The urotheliogenic hypothesis 
Urgency originating from the bladder urothelium/suburothelium. Urothelial cells 
respond to local chemical and mechanical stimuli and send chemical signals to 
bladder afferent nerves. Urothelial cells may have “sensor molecules” that sense 
mechanical and chemical stimuli and then release adenosine triphosphate, 
prostaglandins, nerve growth factor and Acetylcholine (Ach) among others, which are 
excitatory or inhibitory on afferent nerves. The “sensor molecules” could be receptors 
of bradykinin, Ach (muscarinic and nicotinic receptors) and noradrenaline (alpha and 
beta)2. There is growing evidence that increased activity of afferent nerves plays a 
role in urgency. The urothelial/suburothelial dysfunction may not lead to detrusor 
overactivity. Urgency UI may be less frequent and frequency more common in this 
subgroup17.  
The urethrogenic hypothesis 
Urgency originating from the urethra. An urethrovesical reflex can be activated when 
small amounts of urine come into the proximal urethra in patients with stress UI, 
inducing detrusor overactivity. Some patients experience urgency when moving from 
lying or sitting position into standing. Urethral sphincter instability has also been 
proposed as a mechanism of urgency from the urethra.  
The supraspinal hypothesis 
Urgency originating from the brain and brainstem. The central neural control over the 
micturition can fail through decreased capacity to handle afferent signals or reduced 
supraspinal inhibitory control. The “brain overactive bladder” can be either with or 
without detrusor overactivity.  
Beside these hypotheses trying to explain the pathogenesis, there are several possible 
co-factors in the development of overactive bladder/urgency2, 17.  
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 Metabolic syndrome is linked to overactive bladder, possibly through 
mechanical load (overweight) stimulating sensory afferent nerves in the 
trigone and bladder neck, systemic inflammation, oxidative stress and insulin 
resistance which results in ischemia and urothelial dysfunction19.  
 Affective disorders are in many studies linked to overactive bladder and 
urgency, with or without incontinence20. The limbic area in the brain is 
involved in emotions and the processing of afferent impulses. The association 
has been shown to be bidirectional with common underlying mechanisms 
resulting in coexistence of the disorders. There are several possible common 
factors: Corticotropin-releasing factor (CRF) and low 5-HT levels in the CNS 
are associated with both affective disorders and urinary frequency and detrusor 
overactivity 13. Central sensitisation with increased response to normal or 
subnormal afferent impulses is also suggested as a common co-factors for 
anxiety/depression and overactive bladder17.  
 Recent years, there has been much attention to the microbiota of the urinary 
tract. The balance of the urinary microbiota is believed to change the bladder 
sensation and possibly the function. There has been a paradigm shift from 
supposing urinary tract to be sterile, to knowledge about bacteria appearing in 
the urinary tract not coming through ascending spread.  
 Beside the mentioned possible reasons for overactive bladder/urgency, there 
can be local reasons in the bladder like bladder infection, bladder tumour, 
bladder stone, and the process of aging, leading to overactive bladder and 
urgency. Suprapontine lesions like cerebrovascular disease, multiple sclerosis 
and Parkinson´s disease and spinal cord lesions can also lead to detrusor over 
activity and incontinence. 
“Idiopathic” overactive bladder/urgency seems to have multiple possible causes and 




7.3.2 Stress urinary incontinence 
Two main mechanisms, often overlapping, for stress UI are described:  
Hypermobility of the urethra 
A hypermobility of the urethra can develop due to failure in the support of the bladder 
neck and urethra from the pelvic floor. The hammock hypothesis is widely accepted 
as the explanation of UI associated with such hypermobility18. Urethra is normally 
supported by the endopelvic fascia which contains the fibromuscular tissue of the 
vagina. This fascia creates a “hammock” where the urethra is being compressed 
during increased abdominal pressure21, 22. This compression together with the urethral 
sphincter pressure prevents involuntary leakage. This support is decreased by damage 
of the fascia as a result of obesity, chronic cough, constipation, childbirth or 
menopause. The urethra then moves downwards without being compressed, and the 
pressure in the urethra will be lower than in the bladder and lead to leakage of urine. 
Surgical treatment with tension-free vaginal tape (TVT) aims to correct or reconstruct 
these dysfunctions and defects. The good results of TVT support the hammock 
hypothesis.  
Weakness of the urinary sphincter 
The second mechanism is a weakness of the urinary sphincter. Damage on nerves and 
muscle cells due to childbirth may cause deficiency of the external and internal 
sphincter. The sphincters may also be damaged as a result of trauma, 
urogynecological surgery, neurological diseases, ageing and diseases leading to 
muscular atrophy18.  
7.4 Urinary incontinence as a health problem 
In this section I will give an overview of different aspects of UI as a health problem: 
some sociological reflections, the epidemiology of UI, how UI affects the women´s 
lives and treatment of UI with emphasis on pharmacological treatment. 
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7.4.1 Sociological aspects of UI 
The smell of leaked urine is stigmatising, and may contribute to reduced social 
activity, and eventually, social isolation. Smell is often interpreted as a sign of 
inadequate hygiene and is therefore a social marker. The tolerance for smell was 
admittedly higher some decades ago, but from the last part of the nineteenth, and 
even more in the first part of the twentieth century, there was a growing health-
political focus on hygienic measures. Smell was a sign of bad hygiene and infect, 
both public and private, and moral, guilt and shame were central in this area23. Anne 
Kveim Lie and Hilde Bondevik´s book “Red and White, about blood and milk in past 
and future” (title translation by Felde) discusses the body fluids linked to the female 
body as both nature and culture24. Body fluids have in many cultures been regarded as 
dirty and unclean, and the anthropologist Mary Douglas describes body fluids with 
the words “matter out of place”, as unclean and transboundary25. Douglas sees the 
body fluids as the most typical metaphor for social disorder and chaos, something 
without control. The culture needs limits and control, and the social body becomes in 
Douglasʼ understanding determinative for how the physical body is perceived24.   
Sanitary pads were commonly used from around 1960, some decades earlier for the 
wealthiest, making it easier to control the leakage socially.   
7.4.2 Prevalence  
Prevalence is the proportion of a particular population experiencing a symptom or 
having a condition or a disease at a defined time point. It can also be defined as the 
number of existing cases divided by population at risk.  
UI is a common issue among women in all ages. It is a stigmatising condition 
associated with shame26, which can contribute to respondent bias and low prevalence 
estimates in observational studies27, 28. The best prevalence estimates are therefore 
regarded to come from population based studies with representative samples, using 
validated symptom-based questionnaires, not focusing only on urinary incontinence29. 
Such studies exist mostly from developed countries.  
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The prevalence rates vary in systematic reviews between 9 and 69%5, 30, 31.  In four 
large population-based studies, with high response rate, the prevalence varied 
between 25 and 47%: In the large Nurses’ Health Study II, the prevalence was 43%32, 
in the Study of Women’s Health Across the Nation, 47%33, and in the Norwegian 
EPINCONT1 and EPINCONT2 the prevalence was 25 and 29%, respectively34, 35.  
Reasons for variation in prevalence 
Even among population-based surveys using the definition recommended by ICS, the 
prevalence vary widely. The variations can be explained by many aspects that are 
general challenges in epidemiologic research, such as issues regarding sampling and 
non-response, selection criteria, definitions and measurement issues5, 36.  
Women with UI may not answer UI queries, or they may underestimate or deny their 
UI because of shame or thinking the condition is within normal. They may also 
respond in greater numbers because an eagerness to tell about the subject bothering 
them. Differences in collection of data may also affect the prevalence. Data may be 
collected through postal questionnaires, telephone interviews, personal interviews or 
questionnaires received at e.g. a screening station, as in our studies.  
Whether the studies include the total adult female population or only the elderly 
women, or if the study group comprise clinical samples, is important for 
representativity, and will influence the result.  
The use of different definitions and measurements are believed to be a major 
contributor to varying prevalence estimates as described under the section about the 
UI definition. A study of 507 women in general practice in Norway, compared 
prevalence estimates when using different definitions. 47% reported UI as any 
involuntary leakage, 31% reported UI when defined as leakage  ≥2 times per month, 
while 19% had UI by the old definition of ICS where involuntary urine loss had to be 
accompanied by a social or hygienic problem6. One problem with the current 
definition is the nature of the condition. UI often starts slowly, and may have a 
transient occurrence, especially during the first years37. 
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 In a study comparing characteristics and UI definitions in five French surveys on UI, 
the studies focusing on UI and using UI-specific symptom-based questionnaires gave 
higher UI prevalence compared to general health surveys including, but not focusing 
on, UI, and with a perception-based definition of UI. The first type of studies with the 
highest prevalence, reported mostly mild UI, while the second type with the lowest 
prevalence reported more severe UI29.  
The challenges with different UI definitions are closely related to the questionnaire as 
an epidemiological tool. The quality of different questionnaires used in 
epidemiological studies of UI, have been evaluated by ICS38. Questionnaires are 
graded as highly recommended if data is published indicating that the questionnaire is 
valid (if the questions cover all important aspects of the condition, if the questions are 
relevant to the condition and have high sensitivity and specificity) and reliable (the 
questionnaire´s ability to measure in a reproducible way).  
Type 
The prevalence of the different types of UI differs by age. For the population as a 
whole, stress UI is the most common type before mixed and urgency UI, as 
demonstrated in a literature review from 2003: the median prevalence of UI was 
27.6% with type proportions of 50% stress UI, 32% mixed UI and 14% urgency UI39. 
This corresponded to the EPINCONT1 study, where 50% of the UI-group had stress 
UI, 36% mixed UI and 11% urgency UI34. A large population-based study from 
China showed an overall UI prevalence of 31.9%, the type distribution was 59%, 
28% and 9% for stress, mixed and urgency UI, respectively40.  
Many studies have shown a peak in the prevalence of stress UI in the fifth decade of 
life, while urgency and mixed UI continue to increase during lifetime18, as shown in 
figure 2.  
Despite stress and urgency UI being regarded as different conditions with different 
pathophysiology, studies have demonstrated a transition between the subtypes. In a 
study of more than 10.000 women, changes in UI status was described over a 2-year 
period: of the women with baseline urgency UI, 4-9% transitioned to stress UI, 16-
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20% to mixed UI, the rest remained with urgency UI. Of the women with baseline 
stress UI, 4% transitioned to urgency UI, 16-23% to mixed UI and the rest remained 
with stress UI. Of the women with baseline mixed UI, 10-11% transitioned to 
urgency UI, 11-15% to stress UI, and the rest remained with mixed UI41. A recent 
large cohort study over eight years among women with UI demonstrated that most 
women with stress and urgency UI continued to experience similar subtype 
symptoms after eight years, while obese women and those with more severe 
symptoms were more likely to remain with or progress to mixed UI. According to the 
nature of the different types of UI, the authors suggest possible pathways of the onset 
of mixed UI: either developing from no UI or developing from severe stress and 
urgency UI37.  
 
Fig 2. The prevalence of stress UI peaks in the fifth decade and then declines. The prevalence of 
mixed and urgency UI continues to increase with age. (Reprinted with permission from Urology5). 
Severity 
The severity of UI can be characterised by describing (1) the frequency of UI with 
severe UI defined by weekly or more frequent urine loss, (2) by describing the 
amount of urine loss with e.g. slight UI as leakage of drops a few times a month, or 
(3) by combining a measure of both frequency and amount of urine loss5, as in 
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Sandvik Severity Index, which is used in this thesis. This index is calculated by 
multiplying the frequency (four levels) by the amount of leakage (three levels), giving 
an index value, which is grouped into slight, moderate, severe and very severe UI.  
Generally, severe UI is more common in urgency and mixed UI compared with stress 
UI, and the prevalence of severe UI increases by age. In the large EPINCONT1 study 
(total UI prevalence 25%), 43 % of the incontinent women had mild UI and 26% 
severe UI, but only 10% stated that their UI gave them much bother or was a large 
problem34.  
Studies specifically measuring severe UI (urinary leakage several times per week), 
have less variations in prevalence, with prevalence estimates of 6-10% in Europe and 
the United States42. In the longitudinal Nurses´ Health Study, women with urgency 
UI or mixed UI were more likely to report severe UI symptoms over follow-up 
compared to women with stress UI at onset, and women with severe UI at onset were 
more likely to convert to mixed UI during follow-up37.  
Age 
The age trends in UI prevalence are described in many review studies1, 5, 18, 30. Here, I 
will present age trends as shown in the EPINCONT1 study34. The prevalence among 
women under 30 years was 12%, and 40% among women over 90 years. There was a 
peak around mid-age with a prevalence of 30% among women 50-54 years. The 
prevalence of severe UI increased with age. Under 45 years, 12% of the incontinent 
women had severe UI, while 44% of the incontinent women in the age group 60+ had 
severe UI.  
The EPINCONT1 study showed that the frequency of stress UI was highest from 25 
to 49 years, with a relative decrease with increasing age. Urgency UI was most 
frequent among the youngest and oldest. Mixed UI increased with age except a 
relatively high fraction in the age group 20-24 years. Severe UI was most common in 
urgency UI (38%) and least common in stress UI (17%). The same study also found 




Studies of the association between UI and ethnicity have been conflicting. Several 
studies have shown a higher prevalence of UI among white women, but some studies 
also show similar prevalence independent of ethnicity18, 27, 36. A recent review 
concludes that stress UI is shown to be more prevalent among white women, whereas 
urgency UI is more prevalent among black women1. 
7.4.3 Incidence and remission 
Incidence is the proportion of a particular population developing a symptom, 
condition or a disease during a defined time period. It is also defined as number of 
new cases divided by population at risk x time interval. Incidence is usually reported 
for 1-, 2-, or 5-year intervals. 
The annual incidence rates of UI vary in one review between 0.9% and 19%43. In 
another review, the incidence was 5-20% and the remission rates 3-12%37. In a 
metaanalysis, age-specific incidence rates were less than 2/1000 person-years before 
age 40, increased to 5/1000 person-years at age 50, decreased to 3/1000 person-years 
at 60-65 and then increased again44.  
Many women with UI have variations in their symptom occurrence, and several 
studies indicate that a large proportion of women with UI have active and inactive 
symptom phases1, 45. In addition, a considerable fraction demonstrate transition 
between UI types over time37, with a general trend of progression into mixed UI1, 41.  
A Norwegian cohort study followed 2230 middle-aged women for 10 years with five 
checkpoints. Of the continent women at baseline, almost half reported to have UI, at 
least once, during the 10 years. Among the individuals with new-onset UI, 49.8% had 
stress UI, 18.3% had urgency and 20.3% had mixed UI. 89.3% started with slight UI, 
none started with severe UI. One-third with new-onset UI developed persistent UI, 
and in this study of women 40-44 at baseline, there was low tendency for shifting 
type or severity46. The reasons for the large variations in incidence and remission 
rates are the same as for prevalence studies. In addition, differences in follow-up time 
may contribute to different estimates. Most of the studies define remission as absence 
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of symptoms following a period of active symptoms, and do not take into account 
that many women have transient remissions, followed by periods with re-occurrence 
of symptoms37. One large population-based study with 6-monthly questionnaires over 
a period of 4 years, suggests that a more accurate prediction of the long-term status of 
UI could be obtained only after 18 month´s observation37.  
7.4.4 Impact of urinary incontinence on individuals 
A. Psychological effects and consequences 
Many aspects influencing a woman´s psychological well-being may be affected of 
having UI. This includes social life and activities, sexual and other interpersonal 
relationships47. A recent review investigated the literature on comorbid psychological 
symptoms in patients with lower urinary tract disorders. They found an 
overwhelming evidence for co-existence in all age groups between psychological 
comorbidities and lower urinary tract disorders generally3. 
In a qualitative and quantitative study of 314 women with UI, emotional well-being 
was the most affected factor in the Incontinence Impact Questionnaire and open-
ended questions. Half to one-third of the patients felt nervous, embarrassed or 
frustrated because of their UI4. In another qualitative study with in-depth interviews 
of 151 women, stigma was associated with UI, but also with frequency and urgency 
without UI. In this study, the stigma of urinary symptoms depended on whether or not 
the incontinence was perceptible. The women feared having an unclean body or 
compromised social identity. There was also a discrepancy between ethnic groups in 
the study; Hispanic people in particular desired to keep their incontinence symptoms 
a secret26. In one qualitative study of people 65 years and more, the participants 
commonly described feelings of embarrassment, humiliation and disgust associated 
with their urinary incontinence48.  
It is reported that women with urgency UI have more psychological symptoms than 
those with stress UI49, 50. This could have to do with urgency UI being more 




B. Physical consequences 
Compared to other chronic disorders, UI is one of the most bothersome conditions 
affecting physical functioning47. UI is associated with morbidity and increased risk of 
hospitalisation and admission to nursing homes51. 
 Physical complications to UI can be rashes and soreness as a result of the skin being 
constantly wet. A wet and warm environment also lead to fungal infections and 
pressure sores52. In a follow-up study of 6000 women with mean age 79 years, 
weekly or more frequent urgency UI was associated with an increased risk of falls 
and non-spine, non-traumatic fracture. Stress UI was not associated with falls or 
fractures53. 
Impact on quality of life (QOL), social life and activities 
UI has been shown to cause a decline in social function and QOL47, 49, 54. Most studies 
find that mixed UI has a higher impact on QOL compared to stress and urgency UI55-
57 One study showed that UI had a larger impact on health related QOL on women 60 
years and more than other chronic conditions58. In the large PURE study of 9487 
women from 15 European countries investigating the patient characteristics 
associated with QOL and bothersomeness of UI in women seeking treatment, UI 
severity was the most important predictor of QoL decrement and bother, regardless of 
type. Women with mixed UI recorded the lowest QOL score. Increasing age was 
positively associated with QOL, assumed to indicate that “with increasing age, 
coping strategies in UI have become part of everyday life, and other conditions may 
affect the women in addition to, or more than UI”54.  UI together with depression, 
seems have an additive effect which affects both physical and mental health, perhaps 
by increasing a person´s negative perception of their illness59, 60.  Two studies have 
shown that concomitant depression increases the condition-specific QOL decrement 
in UI57, 61.  
7.4.5 Treatment of UI 
We distinguish between conservative treatment approaches in contrast to surgical and 
pharmacological treatment. It is generally recommended that conservative approaches 
at a primary care level should be the initial management for women with all types of 
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UI2. I will give a short overview of the non-pharmacological treatment options, and 
then focus on the pharmacological treatment of UI, which is an important subject in 
this thesis. 
Non-pharmacological treatment 
Non-pharmacological treatment includes lifestyle modification, pelvic floor muscle 
training, scheduled voiding regimens, weighted vaginal cones, electrical stimulation, 
magnetic stimulation and posterior tibial nerve stimulation2. 
Weight loss is recommended to overweight women with UI62. It is still uncertain how 
physical activity interacts with UI. A recent review found some evidence for 
increased rates of stress UI among physically active women63. Non RCT evidence 
suggests that moderate exercise decreases the incidence of UI2, 64. Current or earlier 
smoking with a high number of daily cigarettes is in cross-sectional studies positively 
correlated with UI65, but there are no RCT evidence for decrease in UI by smoking 
cessation.  
Pelvic floor muscle training, bladder training, electric and magnetic stimulation and 
surgery are all shown to be able to resolve UI66. Pelvic floor muscle training is a 
cornerstone in the treatment of UI, first for stress UI, but in recent years also for 
urgency UI, as pelvic floor muscle contraction also can be used to occlude the urethra 
to prevent leakage during detrusor contraction2. Timed voiding and bladder training 
are effective treatments for overactive bladder and urgency UI67. A systematic review 
found a median cure rate of 82.3% for surgical treatment of stress UI66. Since the 
Mid-urethral sling (MUS) procedure was introduced in the 1990s, it has been the 
main surgical procedure for stress UI.  
Pharmacological treatment of overactive bladder and urgency UI 
Anticholinergic drugs are the most used drug group as treatment for overactive 
bladder and urgency UI. Acetylcholine is the primary contractile neurotransmitter in 
the detrusor muscle. The anticholinergic drugs inhibit the binding of acetylcholine to 
the muscarinic receptors of the detrusor smooth muscle cells. They diminish 
intravesical pressure, increase the volume threshold for micturition and reduce 
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detrusor contractions by inhibiting cholinergic nerve stimulation from 
parasympathetic nerves68.  Because the effect of muscarinic receptors is not selective 
for the bladder wall, anti-cholinergic side-effects are frequent. They include dry 
mouth, constipation, headache and blurred vision. There are also possible cardiac side 
effects with increase in heart rate, QT prolongation and induction of ventricular 
tachycardia (torsades de pointes). Caution is especially recommended in frail old 
people. A review article from 2017 found that urgency UI was treated mostly with 
antimuscarinic medications and the median cure rate was 49%66.  In one study from 
HUNT, 38% of new anticholinergic drug users were still taking the drug after one 
year69. In a systematic review of pharmacological treatment effects in elderly with UI, 
there was a small, but significant effect of anticholinergics on urgency UI. Only 
oxybutynin was studied in the frail elderly population, and this drug had no effect on 
UI or quality of life in this subgroup. The authors concluded that pharmacological 
treatment with drugs for urgency UI in the frail elderly is not evidence based70. 
Table 3 shows the different anticholinergic drugs available in Norwegian pharmacies. 
Mirabegron was not introduced on the Norwegian market until 2012, and was not in 
sale when our HUNT3-data were collected.  
Table 3. Anticholinergic drugs available in Norwegian pharmacies. 
Generic name Product name 
  
Tolterodine Detrusitol ® 
  
Oxybutynin Kentera ® 
  
Solifenacin Vesicare ® 
  
Darifenacin Emselex ® 
  
Fesoterodine Toviaz ® 
  
Mirabegron Betmiga ® 
 
Pharmacological treatment of stress UI: Duloxetine 
To treat stress UI, one can aim for an increase in bladder capacity, or an increase in 
bladder outlet resistance. Duloxetine hydrochloride is a dual serotonin and 
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noradrenaline reuptake inhibitor (SNRI) used as an antidepressant drug and is sold in 
Norway under the brand name Cymbalta®. It has a well-established use in major 
depression and generalised anxiety disorders and is also approved for chronic diabetic 
neuropathic pain.  
Duloxetine increases bladder capacity and the activity in the striated urethral 
sphincter, probably through increased levels of 5-HT and NA in the pudendal 
presynaptic neuron in Onuf´s nucleus, leading to stimulation of the pudendal motor 
nerve71, 72. Increased serotonergic activity reduces the parasympathetic and enhance 
the sympathetic nerve activity, supporting the storage of urine. Studies of duloxetine 
in cats showed that the effect of duloxetine on the bladder was mediated centrally 
through both motor efferent signals and afferent sensory signals. The 5-HT2 receptor 
was involved in this process.  
From 2004, duloxetine was approved in many western countries for stress UI after 
RCTs showed efficacy. In a double-blind, randomised, placebo-controlled study of 
stress UI, the decrease in UI episode frequency was 41% for placebo, 54% for 
duloxetine 20 mg daily (p=0.06), 59% for duloxetine 40 mg daily (p= 0.002 and 64% 
for duloxetine 80 mg daily (p<0.001). One half of those at the 80 mg daily dose had 
>64% reduction in incontinence episode frequency (p<0.001 versus placebo). In this 
study discontinuation rates because of adverse effects were 5% for placebo and 9, 12 
and 15% for duloxetine 20, 40 and 80 mg per day, respectively (p= 0.04) No adverse 
effects were considered to be severe73. One study found that duloxetine was poorly 
tolerated and that two thirds of the patients had discontinued the therapy because of 
adverse effects or lack of efficacy after one month treatment74. In most western 
countries the license failed because of adverse events including nausea and suicidal 
thoughts18. The drug was withdrawn from the Norwegian market in 2007. 
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7.5 Risk factors for UI 
Table 4 summarises the effect of potential risk factors on UI. Most epidemiological 
studies on UI are cross-sectional, giving no evidence of causation. ICI 6th edition 
emphasises the importance of focusing on the risk of incident UI2. 
 Increasing age is a risk factor for UI, especially urgency and mixed UI32, 34. For 
stress UI, age is a risk factor only until the fifth decade, probably due to vaginal birth, 
which is a strong risk factor for stress UI only in the two first decades after child 
birth75, 76.  
Table 4.  Risk factors for UI subtypes (with permission from Int Urogynecol J1, expanded) 
Risk factor UI subtype 
    
 Stress UI Urgency UI Mixed UI 
    
<50 years of age ++ + + 
    
≥50 years of age No impact ++ ++ 
    
Parity ++ No impact + 
    
Obesity ++ ++ ++ 
    
Black (white=ref) -- ++ - 
    
Hispanic (white=ref) - - -- 
    
Surgery for stress UI -- + - 
    
Hysterectomy ++ - - 
    
Hormone replacement therapy ++ + + 
    
Family history + No impact + 
    
Smoking ++ + ++ 
    
Diabetes + ++ ++ 
    
Dementia + + + 
    
Asthma/COPD + + + 
    
Heart failure + + + 
    
Ischemic heart disease + + + 
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Changes in hormones and tissues related to menopause have been regarded as an 
explanation for the influence of age on UI.  The prevalence according to age, type and 
severity is discussed in chapter 7.4.2. 
Pregnancy and childbirth are established risk factors for stress UI, probably due to 
injury of the pelvic floor musculature, connective tissue, and nerves77. Parous are 
more likely to have UI than nulliparous, but the difference seems to disappear after 
midlife, in one study after 65 years of age76. In a meta-analysis, vaginal delivery was 
connected with an almost two-fold increased risk of stress UI compared with 
caesarean78. In a recent study, where pregnancy increased the prevalence of UI from 
20% to 30%, vaginal delivery additionally increased the prevalence of UI to 43%. 
The protective effect of caesarean delivery was a 30% reduction of UI and a 35-52% 
reduction of more severe grades of UI. The differences between vaginal and 
caesarean delivery was unaffected by age, but the study group included women only 
up to 65 years75. Compared to other vaginal deliveries, forceps delivery is associated 
with increased long-term risk of stress UI79.  
High BMI is associated with all subtypes and severities of UI80. High BMI is also 
associated with progression to more severe UI64. 
Family history of UI is shown to be a risk factor for stress and mixed UI. Daughters 
of mothers with any UI had in EPINCONT1 an OR of 1.4 (1.3-1.6) of having UI, if 
also the grandmother had UI, the OR was 2.9 (1.1-7.7)81. 
Hysterectomy is associated with development of UI, especially stress UI. In a review 
of 12 papers, the summary OR for UI among women over 60 years with 
hysterectomy was increased by 6082, 83. 
Cigarette smoking, both former and current smoking, is associated with UI. One 
study showed an association only for smoking ≥ 20 cigarettes daily, strongest for 
severe and mixed UI. Smoking is associated with chronic cough, which can 
contribute to stress UI65, 77.  
39 
 
Hormone replacement therapy with oestrogen substitution was earlier assumed to be 
beneficial for UI in postmenopausal women84. Several recent studies have shown, 
however, that oestrogen, alone or in combination with progestin, can predispose to 
UI85.  
Comorbidities are in cross-sectional studies associated with UI. A review 
investigating comorbidities and personal burden of urgency UI, showed that urgency 
UI was associated with falls in elderly persons, depression, urinary tract infections, 
diabetes and deaths51. 
 Diabetes is shown to be associated with UI in several studies. In EPINCONT1, 
the prevalence of UI increased from 26% (no diabetes) to 39% (having 
diabetes), and the diabetic women had more mixed and urgency UI and more 
severe UI. None of the diabetes related variables as blood-glucose or type of 
diabetes was associated with UI86, 87. In one cross-sectional study of women 
50-90 years, UI was associated with insulin-requiring diabetes mellitus, but 
not non-insulin-requiring diabetes mellitus88. 
 Acute urinary tract infection is a cause of transient UI. UI can also lead to 
urinary tract infection89.  
 Dementia is in several cross-sectional studies shown to be strongly associated 
with UI. In addition, longitudinal studies have shown an association between 
cognitive impairment/dementia and incidence of UI90, 91. Treatment for 
reversible dementia has also been shown to improve UI92, and dementia is now 
regarded as a cause of UI2.  
 Ischaemic heart disease is associated with risk factors for UI, especially BMI 
and age. High mortality rate and exclusion of those who die can cause bias 
(Neymans bias), and contribute to failure to identify an association between 
ischaemic heart disease and UI2. In the Nurses´ Health Study, coronary heart 
disease was associated with both incident weekly UI and incident severe UI. In 
EPINCONT1 angina pectoris was associated with any UI and severe UI86.  
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 Stroke is shown to be associated with UI. According to a review article, 28-
79% of stroke-survivors experienced UI, with detrusor overactivity being the 
most common type of incontinence by urodynamic studies93. 
 Asthma and chronic obstructive pulmonary disease seem to be associated with 
UI94, 95. The mechanism is probably chronic cough and accompanying increase 
of intraabdominal pressure. Association has also been showed between UI and 
functional impairments generally, mobility limitations, a history of falls, 
arthritis and use of walking aid96-98.  
Socio-economic status (SES) is correlated negatively with many of the mentioned 
factors, including BMI, diabetes, depression, smoking and physical activity. Higher 
SES is on the other hand associated with increased care-seeking for UI, and could 
therefore lead to more reporting of symptoms, but it is uncertain evidence for an 
association between SES and UI prevalence. In the National Health and Nutrition 
Examination Survey (NHANES), urgency UI was found to be associated with low 
socioeconomic status measured by poverty income ratio (PIR), which reflects the 
family income99. 
High impact exercise is associated with stress UI. On the other hand, women with UI, 
especially severe, often experience a barrier for being active in sports100. Cross-
sectional studies suggest that low impact sports can be protective and high impact 
sports harmful for UI65, 101. In a prospective study from 2018 among women with UI, 
more physical activity was associated with lower odds of progression to severe UI64. 
7.5.1 Depression and anxiety associated with UI 
As early as in 1964 a relationship between common affective disorders and UI was 
described102. In 1987, Macaulay et al assessed the mental state of patients attending 
an urodynamic clinic. They found more anxiety- and depression symptoms among 
women with UI, especially was anxiety associated with detrusor instability and 
sensory urgency. The same study also demonstrated effect on urgency symptoms of 
psychotherapy treatment103. In 2011, ICS organised a think-tank on psychological 
factors and LUTS. It was concluded that not only overactive bladder and the urgency 
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spectrum, but also other LUTS, may be associated with affective conditions, and that 
a possible causation or maintenance of LUTS through psychological causes needed 
further research20. Most studies on the field are about the association between 
depression and UI. 
Depression and UI 
Several cross-sectional and longitudinal epidemiologic studies have shown an 
association between depression and urinary incontinence61, 91, 98, 104, 105. A majority of 
the studies are cross-sectional. According to type, studies show an association to all 
three main types of UI, but strongest for urgency and mixed UI57, 106-108.  
In two longitudinal studies, depression at baseline predicted onset of UI, but UI at 
baseline did not predict onset of depression104, 109. Another study showed that 
depression symptoms at baseline were associated with persistence, but not incidence, 
of UI110. UI four months after giving birth was in one study associated with 
depression 12 months postpartum111.  
Some studies focus on quality of life and functional status among patients with co-
occurrence of UI and depression. Generally, incontinent women with co-morbid 
depression state their UI as significantly more severe, have more quality of life 
impairment and greater decrements in functional status compared to the incontinent 
women without depression61, 112. The most important references on the association 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Anxiety and UI 
As for depression, anxiety seems to be strongest associated with urgency and mixed 
UI57, 113. In one longitudinal study, urgency UI predicted incidence of anxiety and 
depression, and anxiety predicted incidence of urgency UI108. In a more recent 
longitudinal study, UI at baseline, only with condition-specific functional loss, 
predicted onset of anxiety disorder. Anxiety at baseline also predicted onset of UI, 
but only if accompanied with condition-specific functional loss119. The most 
important references on the association between UI and anxiety are listed in Table 5. 
7.5.2 Drugs associated with UI  
Several drug classes have been found to be associated with UI. The most important 
are antidepressants, antipsychotics, benzodiazepines, non-benzodiazepine 
anticonvulsants, beta receptor agonists, alpha blockers, estrogens, antihistamines, 
beta blockers, diuretics, calcium channel blockers, angiotensin converting enzyme 
(ACE) inhibitors and angiotensin II receptor blockers120-126. The psychotropic drugs 
are related to this thesis and will therefore be in focus here.  
Drugs can lead to incontinence by increasing intravesical pressure and/or lowering 
bladder outlet resistance. Both mechanisms disturbe the pressure balance between the 
bladder and the urethra and lead to UI. Drugs can also cause UI by disturbance of the 
central nervous control of voiding or through an overproduction of urine.  
Psychotropic drugs 
Several studies have shown an association between UI and psychotropic drugs, 
especially antidepressants120, 121, 124, 125. The psychotropic drugs with some evidence 
for association with UI are summarised here:  
Antidepressants  
Antidepressants influence UI mostly through the adrenergic, noradrenergic and 
serotonergic systems. Several serotonergic and noradrenergic pathways are involved 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































noradrenaline are important neurotransmitters regarding micturition control. 
Serotonergic antidepressants may induce UI by affecting these pathways. SSRIs and 
SNRIs have been assumed to act on 5-HT4 receptors in the bladder detrusor, causing 
overactivity of the detrusor and potentially overactive bladder with or without 
urgency UI15. 5-HT2A receptors in the bladder wall may also be involved, especially 
in the control of urethral function128, 129. In a study in rats, the activation of 5-HT1A 
receptors was involved in the pathogenesis of UI16. In a retrospective follow-up study 
investigating the incidence of UI (defined by initiation of spasmolytic drugs or 
absorbent products) among users of SSRIs, the adjusted relative risk (RR) for UI due 
to SSRI use was 1.61 (1.42-1.82), higher among the oldest persons. Among the 
SSRIs, sertraline was strongest associated, with RR 2.76 (1.47-5.21)124. In a 
prospective trial with 113 women taking antidepressants and 92 healthy controls, the 
prevalence of overactive bladder was significantly higher in antidepressant users 
(64%) than in the control group (33%) (p=0.003). In this study, users of fluoxetine 
had higher prevalence of overactive bladder than those using sertraline125.  However, 
some studies have found no association between antidepressants and UI122, 123. The 
tricyclic antidepressants also inhibit reuptake of serotonin and noradrenaline, but 
have also an anticholinergic effect, and can therefore theoretically also stimulate 
storage of urine. The different antidepressant classes according to mechanism of 
action are shown in Table 6. 
Antipsychotics  
Antipsychotics act in the dopaminergic, adrenergic and noradrenergic systems. They 
are both dopamine receptor antagonists and alpha blockers, and could therefore 
possibly lead to UI. Second generation (atypical) antipsychotics are also serotonin 5-
HT2A receptor antagonists, and could influence the bladder function through that 
system130. One study showed that atypical antipsychotics were associated with 
increased prevalence of LUTS123, but other studies have showed no association122, 131 
However, many antipsychotics also have anticholinergic effects and could therefore 




Table 6. Antidepressants according to neurobiological mechanism 
Antidepressant group, mechanism Generic names 
Selective inhibitors of reuptake of serotonin in the synapse (SSRI) citalopram, escitalopram, 
fluoxetine, fluvoxamine, 
paroxetine, sertraline 
Selective inhibitors of re-uptake of serotonin and noradrenaline in the 
synapse (SNRI) 
duloxetine, venlafaxine 
Serotonin re-uptake inhibitor with receptor modulation in the synapse vortioxetine (from 2015) 
Selective inhibitor of re-uptake of noradrenaline in the synapse reboxetine 
Inhibitors of re-uptake of dopamine and noradrenaline in the synapse 
(NDRI) 
bupropion 





Blockers of natural decomposition of monoamines fenelzin, tranylcypromin 
(irreversible blockers), 
moklobemid (reversible blocker) 
Receptor antagonists (blocking of pre-synaptic α2-receptors) mianserin, mirtazapin 
 
Benzodiazepines  
Benzodiazepines may cause UI through their effect on GABAA-receptors in the CNS 
and relaxation of striated muscle120. In a study of 4583 nursing home residents, users 
of benzodiazepines had a statistically significant increased risk (OR 1.44) of having 
UI132.  
Non-benzodiazepine anticonvulsants  
Non-benzodiazepine anticonvulsants were in one study associated with UI 122. Other 
studies and case reports have also found and described an association between some 
anticonvulsants and UI133-135. The drugs in this group have diverse mechanisms of 
action, and it is unclear whether these drugs have a common mechanism for their 
possible association with UI.  
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7.6 Anxiety and depression. 
In this section I will shortly describe the symptomatology, epidemiology and some 
neurobiological mechanisms of anxiety and depression. The next section will then 
focus on possible mechanisms for the associations between UI and anxiety and 
depression. 
7.6.1 Anxiety 
Anxiety disorders are a group of conditions characterised by inner turmoil, tension 
and anxiety accompanied by physiological symptoms in situations where there is no 
real danger. Common for the different types of anxiety disorders is symptoms of 
autonomous activation such as palpitations, symptoms from chest and stomach 
(heavy breath, chest pain and nausea), changes in state of mind, dizziness and sensory 
symptoms. Unspecific symptoms like memory problems, concentration problems, 
generalised muscle pain, fatigue and loss of energy are also common symptoms. 
Panic disorder, generalised anxiety disorder, post-traumatic stress disorder and 
phobias are among the most common anxiety types. 12-month prevalence was 18% 
for any anxiety disorder and lifetime prevalence 29% in a review from the United 
States136.  
7.6.2 Depression 
Mood disorders are among the most common reasons for functional loss in the 
population. Depression is, by WHO, ranked as the third most important cause of 
burden of disease137. There are two main groups of mood disorders: single or repeated 
depressions and bipolar disorders. Most epidemiological studies focus on moderate 
and severe depressions, often called major depression. The one-year prevalence of 
major depression is in most western studies approximately 6%. Lifetime prevalence is 
estimated to 15-18%138. Depression is associated with increased mortality and diverse 
somatic morbidity139. A recent review conclude with a high rate of comorbidity in 
depression and a wide range of somatic comorbidities, and these conditions are often 
worse when depression is present140.   
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There is no single mechanism which can explain all episodes of depression. Both 
psychosocial and biological stressors may contribute to the pathophysiology in 
depression138. Two causal hypotheses will be mentioned here:  
 The monoamine hypothesis: The level of monoamine neurotransmitters 
(serotonin, dopamine, noradrenaline) are reduced in depression.  
 Hypothalamic-pituitary-adrenal (HPA) axis changes: Increased levels of 
plasma cortisol are found in severe depressions due to changes in the HPA 
axis with stress-related cortisol release. 
7.6.3 Neurobiological aspects in anxiety and depression 
I will shortly present the most common neurotransmitters and their receptors, 
associated with anxiety and depression:  
Serotonin (5-HT) 
Animal studies and preclinical studies on humans have shown that the serotonergic 
system plays a central role in anxiety and depression. Serotonin (5-HT) is synthesised 
from tryptophan in serotonergic nerve cells in the brain stem. 5-HT is also found in 
the hypothalamus, in the limbic system and frontal cortex. 5-HT has general 
modulating effect in the brain. It affects sleep, appetite, aggression, sexual function, 
pain and emotions like anxiety, depression and irritability. 5-HT is removed from the  
 
Table 7. Effects of blockade and stimulation of serotonin receptors (Based on ref.141) 
Receptor Effect of stimulation Effect of blockade 
5-HT1A Reduced depression, anxiety 
and obsessive thoughts 
Increased depression, anxiety, 
obsessive thoughts, irritability 
5-HT2A Behavioural activation. 
Insomnia, anxiety and 
agitation. Sexual dysfunction. 
Reduced behavioural 
activation, better sleep, 
reduced sexual dysfunction 
5-HT2C Irritability, reduced appetite Reduced irritability, better 
appetite 
5-HT3 Feeling of seasickness, nausea 
and headache 
Attenuates the feeling of  




synapse by a 5-HT transporter. SSRIs inhibit this transport and increase the level of 
5-HT in the synapse. There are many different 5-HT receptors, and the effects of 
stimulation and blockade of some of them are summarised in Table 7. Especially 5-
HT1A plays a role in anxiety and depression modulation. Stimulation of 5-HT1A leads 
to reduced depression, anxiety and obsessive thoughts. Inhibition of 5-HT1A has the 
opposite effect. 
Noradrenaline (NA) and adrenaline  
These belong to the catecholamines. Dopamine is broken down to NA and adrenaline. 
Acute stress leads to release of NA in the limbic system. NA-dependent stimulation 
of α1-receptors leads to increased release of glutamate and thus increased excitatory 
activity. There are two main types of adrenergic receptors: α (alfa)- and β (beta)-
receptors. These are abundant both in the central nervous system, and in peripheral 
tissues, like in the heart and the urinary bladder141. 
Dopamine 
Dopamine is produced in the thalamus and midbrain and nerves with dopamine 
innervates the pituitary gland, the basal ganglia, and large parts of the cortex, 
especially prefrontal cortex. Dopamine is connected to emotions, cognitive functions 
and reward. Dopamine plays an important role in Parkinson´s disease and 
schizophrenia. In certain types of depression, synaptic dopamine levels can be 
reduced, especially in depressions with motoric retardation and somatic symptoms. 
The antidepressant bupropion acts partly through inhibition of reuptake of dopamine 
in the pre-synapse. The main effect of anti-psychotic medication is blockade of the 
post-synaptic dopamine receptors141.  
Glutamate 
Glutamate has an excitatory effect. Several studies have demonstrated associations 
between pathology in the glutamate system and mental disease141. The drugs 
memantin and lamotrigine reduce the release of glutamate (lamotrigine also affects 




GABA (-aminobutyric acid) 
 GABA has an inhibitory effect. Benzodiazepines and barbiturates as well as alcohol, 
work through binding to GABA-receptors. Some other anticonvulsives also affect 
GABA-receptors. Changes in the GABA system are found in anxiety, depression and 
psychoses141.  
7.7 Possible mechanisms for the associations between UI 
and depression and anxiety 
Biological explanations 
Biological theories for the association between depression and anxiety and UI are 
linked to the serotonergic and noradrenergic systems. Dysregulation of 5-HT and NA 
in the brain is strongly associated with depression and anxiety. Serotonergic activity 
inhibits voiding, by inhibiting the parasympathetic input to the bladder and enhancing 
the efferent control of the urethral outlet. Low levels of 5-HT and NA in the CNS 
could therefore lead to UI. 
It is also known that 5-HT and NA modulate pain sensitivity through their presence in 
the descending pain pathways. Descending serotonergic and noradrenergic pathways 
suppress the peripheral afferent input, such as musculoskeletal and abdominal pain, in 
a way that makes a healthy person more able to pay attention to what happens outside 
the body. Dysfunction of the descending inhibitory pathways allows stronger 
ascending signals to reach the brain where they are interpreted as pain. This can 
explain the symptoms of physical pain associated with depression14. Figure 3 
demonstrates the role of 5-HT and NA in UI, depression and pain, as shown in the 
paper of Thor et al14. 
Psychological explanations 
UI has been shown to have high impact on quality of life, especially severe UI and 
urgency and mixed UI4, 47, 142. UI can impair social life and outdoor activities, such 
factors are potential risk factors for depression. Being afraid of losing control over 




Figure 3. The role of serotonin (5-HT) and noradrenaline (NA, here norepinephrine,NE) in UI, 
depression and pain. In UI: 5-HT and NE facilitates glutamate´s exitatory effect on the pudendal 
nerve activity in Onuf´s nucleus, leading to contraction of the external urethral sphincter. In 
depression: Low levels of 5-HT and NE in the brain are associated with depression. In pain: Low 
levels of 5-HT and NE leads to failure of the normal descending inhibitory function of 5-HT and NE 
on the ascending pain signals e.g. from the musculoskeletal system. (Reprinted with permission from 
The International Journal of Clinical Practice14). 
 
behaviour. Perry et al presented a model for understanding how psychological factors 
may cause, maintain or exacerbate symptoms of urgency UI, and also, how such 
factors may impede therapeutic interventions that require motivated patients. The 
authors highlight the importance of paying attention to women´s perceptions, beliefs, 
assumptions and expectations the about the ability to control micturition. Motivation 
and confidence in learning new skills and cope with failures is also important108. This 





Figure 4. Bladder filling perceived as a threat which leads to anxiety and selective attention to 
bladder fullness and an overwhelming urgency (upper part of the figure). This leads to the 
misinterpretation of a weak bladder and risk of wetting. This perception can lead to an avoidance 
behaviour and increased anxiety. The lower part of the diagram integrates in the model the emotional 
consequences of the anxiety- and avoidance circle, with depression, shame and decreased confidence, 
social consequences with isolation and decreased daily activities, and negative treatment 
consequences. (Reprinted with permission from British Journal of Health Psychology108). 
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8. Aims of the study 
The main objective of the thesis was to investigate the relationship between female 
UI and anxiety and depression in three general populations. In the last paper we also 
aimed to investigate the relationship in light of the use of psychotropic drugs. The 
studies performed had the following specific aims:  
Paper I. To determine the association between anxiety and UI, and depression and 
UI, among middle-aged women in a large population-based cross-sectional study, and 
to investigate the association for type and severity of UI.  
Paper II. To predict the odds of developing anxiety and depression among women 
with UI at baseline compared to those without UI at baseline, and to predict the odds 
of developing UI among women with anxiety and depression at baseline compared to 
women without these conditions at baseline. In addition, we aimed to further 
investigate these connections in different age groups, and between different levels of 
anxiety- and depression scores, and for stress- and urgency components of UI.  
Paper III: To investigate the possible impact of psychotropic drugs on the 
associations between anxiety and depression and UI.  
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9. Material and methods 
In this section, I will present the databases used in this thesis; The Hordaland Health 
Study (HUSK) used in Paper I, The Nord-Trøndelag Health Survey 2 and 3 (HUNT2 
and HUNT3) used in Paper II and Paper III and The Norwegian Prescription 
Database (NorPD) used in Paper III. I will further present the UI variables and 
classifications, as well as the anxiety- and depression variables and classifications 
used in the studies. Finally, the statistical methods used in the papers and the ethical 
approvals will be described.  
9.1 The Hordaland Health Study (HUSK) 
HUSK was a population-based survey conducted in Hordaland county, now part of 
Vestland county, in western Norway from 1997-1999. It is part of COhort of 
NORway (CONOR), a national research collaboration including 
Tromsøundersøkelsen, Helseundersøkelsen i Nord-Trøndelag (HUNT) and 
Helseundersøkelsen i bydelsregioner i Oslo (HUBRO). HUSK was a collaboration 
between the National Health Screening Service (now part of National Institute of 
Public Health), the University of Bergen and the Municipal Health Services in 
Hordaland. The main focus of HUSK was on chronic diseases, including 
cardiovascular disease, cancer, osteoporosis, anxiety and depression, urinary 
incontinence and drug use.  
Study group in Paper I 
All persons born between 1953 and 1957 who lived in the county of Hordaland were 
invited by mail to participate in HUSK, altogether 29.400 (14.349 women). A total of 
8.584 men (57%) and 9.976 women (70%) met at a screening station (office or bus) 
for blood tests and some examinations, and here they received Questionnaire 1, which 
they filled in at home and returned by mail. 8.843 women (89%) answered and 
returned Questionnaire 1. 7.039 women received Questionnaire 2, including questions 
about urinary incontinence, anxiety and depression. 5.321 women (76%) answered, 
and this represented the study group in Paper I.  
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The questions about UI, anxiety and depression in HUSK are identical with the 
questions in HUNT (with exception of 25% of the questionnaires in HUNT2 which 
only had three instead of four frequency-levels on UI), and will be described under 
the description of the EPINCONT-study. The HUSK questionnaire is also shown in 
appendix.  
9.2 The Nord-Trøndelag Health Survey (HUNT) 
The Health Study in Nord-Trøndelag is the largest population-based collection of 
health data in Norway. Three surveys were carried out, HUNT1 in 1984-1986, 
HUNT2 in 1995-1997 and HUNT3 in 2006-2008. In addition, three waves of a 
Young-HUNT Study were carried out, including participants aged 13-19 years. 
HUSK and HUNT are both part of the national research collaboration CONOR. The 
HUNT studies covered a broad spectre of medical topics including health problems 
from most organ systems and mental health, in addition to lifestyle factors and quality 
of life. The HUNT2 and HUNT3 surveys are partly designed as follow-ups of the 
previous study, but the HUNT studies have also expanded.  
In all three HUNT surveys, all persons aged 20 years and older in the former county 
of Nord-Trøndelag (Nord-Trøndelag was from 01/01/2020 part of the county 
Trøndelag) were invited to participate. The participation rate declined from HUNT1 
to HUNT3. In all three surveys, more women than men participated, and the middle-
aged and elderly (50-79 years) had the highest participation rate. The invitation 
included Questionnaire 1 (Q1), which the participants were asked to bring to a 
screening station together with the written consent. At the screening station they 
underwent clinical examinations and blood samples were drawn. At the screening 
station the woman received Questionnaire 2 (Q2). In HUNT2, the questions about 
anxiety and depression were in Q1, and the questions about UI were in Q2. In 
HUNT3 the questions about anxiety, depression and about UI were in Q2.  
The HUNT database is continuously being adjusted to increase data quality. This 
results in small changes over time in numbers of invited and attended persons in the 
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surveys. When we received the data file for the third paper in 2017, we got a different 
total number of invited women and women who had answered Q1 and Q2. One 
reason for changes is also retraction of written consent from some participants. The 
participant numbers in HUNT3 used in the flowchart, are the numbers from the file 
we received in 2017.  
Study group in Paper II 
The study group for Paper II consisted of women who answered the questionnaires 
about anxiety, depression and UI in both HUNT2 and HUNT3. 47.177 women were 
invited to participate in HUNT2 and 47.415 women were invited in HUNT3 
according to information from HUNT at the time we received the data file for Paper 
II. 34.662 (73.5%) answered Q1 and 30.268 women answered Q2 in HUNT2. 27.761 
women answered Q1 and 23.142 answered Q2 in HUNT3. The study group consists 
of the 16.263 women who had answered both Q1 and Q2 in HUNT2 and Q2 in 
HUNT3.  
Study group in Paper III 
The study group in Paper III consisted of women who had answered the questions 
about anxiety, depression and UI in HUNT3. According to information from HUNT 
at the time we received the data file for Paper III, 47.293 women were invited in 
HUNT3, a total of 27.758 (59%) women answered Q1 and 27.691 women received 
Q2. These were our source population. 23.141 women answered Q2 and 21.803 
(79%) of these answered the UI part of the questionnaire, and these were our study 
population (EPINCONT2).  
Both a study of the cohort-profile and a study of non-responders in HUNT3 have 







Fig 5. Participation in HUNT2 and HUNT3, and study groups in Paper II and Paper III. 
 
9.2.2 The EPINCONT study  
EPidemiology of INCOntinence in the county of Nord-Trøndelag (EPINCONT) is the 
name of the sub study about UI in the HUNT studies. EPINCONT1 is the study based 
on the UI questionnaire in HUNT2, and EPINCONT2 is the study based on UI 
questions in HUNT3. The questionnaire was designed by Steinar Hunskår and Hogne 
Sandvik in the Research group for urinary incontinence at the Department of Global 
Public Health and Primary Care at the University of Bergen.  
9.2.3 Classification of UI variables 
The questions about UI in HUSK are similar to the UI questions in EPINCONT. In 
EPINCONT1, 25% of the questionnaires had three instead of four categories on 
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frequency of leakage, due to a mistake at the HUNT data centre. This did not 
influence the studies in this thesis, because severity of UI was not part of the analyses 
in Paper II, where the HUNT2 database was used. 
UI was defined as any leakage of urine10. The UI questions started with an entry 
question about experiencing involuntary loss of urine or not. If the answer was yes, 
the woman was asked more specific questions: how often do you leak (four levels), 
how much leakage amount (three levels), do you leak when coughing, sneezing, 
laughing, lifting heavy items (yes/no).  
Those who, despite answering “no” or failing to answer on the entry question, 
answered confirmatively on the questions about frequency, volume, and type of 
leakage, were also regarded as answering “yes” on the entry question. Those not 
answering the entry question about leaking urine or not, and answered two or less of 
the following three questions, where classified as missing.  
If the woman leaked urine when coughing, laughing, sneezing, or making an effort, a 
stress component was defined. If she answered “yes” on the question about urgency 
to void, an urgency component was defined. If answering “yes” on both these 
questions, the leakage was defined as mixed UI. Those who answered “no” on both 
the urgency and stress UI question, despite answering “yes” on the entry question 
about loss of urine, were grouped as other/unclassified.  
To categorise the severity of the UI, a four-level severity index (Sandvik Severity 
Index) developed by Sandvik et al. was used145, 146. The reported frequency (four 
levels) was multiplied with the amount of leakage (three levels), resulting in an index 
with 12 levels, which was further categorised into slight (1-2), moderate (3-6), severe 
(8-9) and very severe (12). Slight incontinence denotes leakage of drops a few times a 
month, moderate incontinence daily leakage of drops and severe incontinence larger 
amount at least once a week. Sandvik Severity Index has been validated against a 48-
hour “pad-weighing” test146. Slight incontinence means a mean leakage of 6 g/24 h, 
moderate incontinence means a mean leakage of 23 g/24 h, and severe incontinence 
means a mean leakage of 52 g/24h and very severe incontinence means a leakage of 
60 
 
122 g/24 h. The Sandvik Severity Index is therefore a semi-objective and quantitative 
measure of the leakage. In both Paper I and Paper III, the categories severe and 
very severe were merged, to achieve statistically stronger groups.  
9.2.4 Classification of anxiety and depression  
The Hospital Anxiety and Depression Scale (HADS) was used to define anxiety and 
depression both in HUSK and HUNT. HADS was first developed in English in 1983 
by Zigmond and Snaith147. It was from the beginning designed to investigate anxiety 
and depression among patients with somatic disease. Somatic symptoms of anxiety and 
depression were therefore excluded to avoid somatic disease to be confused with 
anxiety and depression symptoms. HADS is a self-administered questionnaire 
consisting of 14 items, seven questions for anxiety (HADS-A) and seven for depression 
(HADS-D). Each item has four possible answers, scored on a Likert scale from 0 to 3. 
The item scores are added giving subscales from 0-21. 0 is minimum and 21 is 
maximum symptom level. Substitution of missing values was performed for persons 
who responded to five or six of the HADS-A and HADS-D questions by assuming 
similar responses on the questions not answered as in those answered. This was done 
by multiplying the obtained score by 7/5 if five of the seven questions were answered 
and by 7/6 if six questions were answered. If one to five questions were answered, the 
person was excluded and coded as missing. 
HADS-A contains questions reflecting restlessness and worry and one question about 
panic attacks. The HADS-D focuses mainly on the aspect of reduced pleasure response 
in depression, but also psychomotor retardation as well as impaired mood. Five of 
seven questions about depression symptoms focus on lack of positive feelings. The 
depression scale covers only two of the three main criteria for depression, according to 
ICD-10 (decreased mood, lack of interest and joy), while somatic symptoms like lack 
of energy and disturbance of sleep and appetite are not covered.  
The developers of the scale recommended three cut-off values: mild (8-10), moderate 
11-14) or severe (15-21) anxiety or depression score. Clinically significant anxiety 
and depression is in this thesis defined as a HADS-A or a HADS-D score of 8 or 
more, respectively. We defined mild anxiety and depression as 8- <11 on the HADS-
A and HADS-D, respectively, and moderate/severe anxiety and depression as ≥11 on 
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HADS-A and HADS-D, respectively. HADS has been validated in several studies148, 
149. In 2016 the Knowledge Centre at the Norwegian Institute of Public Health 
undertook a review and assessment of all psychiatric measures used in Norway, 
among them, the Norwegian HADS. The properties of the scale were considered by 
norm data, reliability and validity. Their conclusion was that the Norwegian version 
of HADS was a relatively well validated screening instrument for symptoms of 
psychological distress150.  
9.3 The Norwegian prescription data base (NorPD) 
The NorPD is a national health register maintained by the Norwegian Institute of 
Public Health. It contains information about all prescriptions dispensed at Norwegian 
pharmacies from 2004. Each time a drug is dispensed, the generic name, Anatomical 
Therapeutic Chemical (ATC) code, strength, number of packages and defined daily 
dose (DDD) are registered. Every record contains the user´s unique identity number, 
which makes it possible to identify chronologically all prescriptions to each 
individual. NorPD lacks individual-level information on medication dispensed to 
institutionalised individuals.  
9.3.1 Classification of drug use  
We defined drug use as one or more dispensed prescription during the last six 
months. In the dose-response analyses we used four different levels of DDD: no use, 
low DDD, medium DDD and high DDD. The cut-off values were set separately for 
each drug, due to different user profiles. The following drug groups were used in the 
analyses: Opioid analgesics (ATC-code: N02A), other analgesics (N02B), 
antiepileptic drugs (N03), lamotrigine (N03A X09), antiparkinson drugs (N04), 
antipsychotics (N05A), anxiolytics (N05B), hypnotics and sedatives (N05c), 
antidepressants (N06A) and selective serotonin reuptake inhibitors (SSRIs) (N06AB).  
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9.3.2 Confounding variables and risk factors adjusted for 
In logistic regression analyses, age was used as a continuous variable (Paper I and 
Paper II) or categorised into 5-year groups (Paper III). In descriptive analyses in 
Paper II and Paper III, and in the logistic regression analyses in Paper II, we 
defined three age groups: 19-39 years, 40-54 years and over 55 years.  
BMI was obtained by using the measures of height and weight from the screening 
stations. The following categories were used in the logistic regression analyses: 
underweight (<18.5), normal (18.5-24.9), overweight (25.0-29.9), obesity (≥30). Data 
were adjusted for BMI in all three papers.  
Parity was regarded as a confounder and was adjusted for in the logistic regression 
analyses in all three papers.  
In Paper I, Paper II and Paper III, we adjusted for the following co-morbidities, 
known to be associated with both depression and UI, and thus possible confounders: 
diabetes, asthma, myocardial infarction and cerebral stroke. In Paper III we also 
adjusted for chronic musculoskeletal pain (fibromyalgia) and rheumatoid arthritis.  
In Paper III we also adjusted for use of oestrogen replacement medication and use of 
urologic medication for overactive bladder and urgency UI. 
9.4 Study design and statistics 
Paper I and Paper III are cross-sectional, population-based studies. Paper II is a 
longitudinal population-based study with a 10-year follow-up time.  
Descriptive statistics were used to characterise the overall study populations in the 
studies.  
Chi-square tests were performed to test differences between proportions in Paper I 
and Paper III: percentage of women with anxiety and depression with and without 
UI (Paper I), percentage of UI among women with and without anxiety and 
depression (Paper III),  percentage of UI among women with and without 
psychotropic drug use and by different daily doses of the drug (Paper III) and 
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prevalence of UI among women with depression/anxiety with and without use of 
antidepressants and anxiolytics (Paper III).  
Confounding and effect modifying variables were evaluated by logistic regression 
analyses and by stratification (Paper III). Multiple logistic regression analyses were 
used in all papers to adjust for confounders.  
Odds ratios were reported with 95% confidence intervals. P< 0.05 was chosen as 
level of statistical significance. SPSS software was used for statistical analyses in all 
studies, version 15.0 in Paper I, version 22.0 in Paper II and 25.0 in Paper III.  
9.5 Ethical approvals 
Ethical approvals for the studies were obtained from Regional and National ethics 
review boards and from the Norwegian Data Inspectorate. For Paper III, Norwegian 





10. Main Results 
The thesis consists of three papers. Paper I was a cross-sectional study of the 
association between anxiety and UI, and depression and UI, among 5321 women aged 
40-44 years in the HUSK study (1997-1999). Paper II was a longitudinal study among 
women 20 years and older in HUNT2 (1995-1997) and HUNT3 (2006-2008) of 
associations between anxiety and depression at baseline and the incidence of UI, and 
also associations between UI at baseline and the incidence of anxiety and depression. 
Paper III was a cross-sectional study from HUNT3 of the association between anxiety 
and UI as well as between depression and UI, and also, the impact of psychotropic 
drugs on this association.  
10.1 Paper I 
The study group in Paper I was women in HUSK who had answered the 
questionnaire including questions about UI and HADS. The prevalence of any UI was 
26%. The proportion of stress, urgency and mixed UI was 53%, 9% and 30%, 
respectively, the remainder had unclassified UI. 58% was classified with slight UI, 
36% with moderate and 5% with severe UI. More than two thirds had experienced UI 
less than once a week, and 68% had a duration of their UI less than 5 years. 
20% had anxiety (HADS-A ≥8) and 6% had moderate/severe anxiety (HADS-A ≥11). 
8% had depression (HADS-D ≥8) and 2% had moderate/severe depression (HADS-D 
≥11). 1496 women had either HADS-A ≥8 (n=1048) or HADS-D ≥8 (n= 448). Of 
these, 329 women had both HADS-A ≥8 and HADS-D ≥8. 73% of the women 
classified as depressed, had also anxiety, while 31% of the women with anxiety had 
also depression, according to our definitions.   
Having UI increased the prevalence of anxiety from 18% to 26% (p< 0.001) 
compared to being continent. Having UI increased the prevalence of depression from 
7% to 12% compared to being continent. Mixed and severe UI had the highest 
percentages of anxiety and depression.  
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In logistic regression, UI was associated with anxiety with OR 1.59 (1.36-1.86) and 
with depression with OR 1.64 (1.32-2.04). All severities and types were associated 
with anxiety, with highest ORs for severe UI with OR 2.30 (1.36-3.88), and for 
mixed UI with OR 2.05 (1.62-2.59). All severities were associated with depression, 
with highest OR for severe UI with OR 2.14 (1.08-4.22). Among types of UI, only 
mixed UI was significantly associated with depression with OR 2.24 (1.65-3.03).  
 
Figure 6. The association between UI, by type, and anxiety and depression (Paper I). 
 
Figure 7. The association between UI, by severity, and anxiety and depression (Paper I). 
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In conclusion, Paper I shows an association between anxiety and UI as well as 
between depression and UI. For both anxiety and depression, the association is 
strongest with mixed UI and severe UI.  
10.2 Paper II 
The study group in Paper II consisted of those women who had answered the 
questionnaires concerning anxiety, depression and UI in both HUNT2 and HUNT3. 
At baseline the prevalence of UI was 24%, 28% among the middle-aged, 17% in the 
youngest age group and 24% in the oldest group. 21% reported a stress component, 
and 10% an urgency component. The stress component was most common among the 
middle aged, and least common among the youngest, while the prevalence of urgency 
component was highest among the oldest. The 10-year incidence of UI was 19%, 
highest for the stress UI component and in the youngest age group.  
At baseline 11% had a mild anxiety score (HADS-A 8-10) and 6% had 
moderate/severe anxiety score (HADS-A ≥11). The prevalence of anxiety was almost 
equal between the age groups. The 10-year incidence of mild anxiety was 8%, almost 
the same in all three age groups. 10-year incidence of moderate/severe anxiety was 
3%, lowest in the oldest group.  
At baseline 7% had mild depression score, and 2% had moderate/severe depression 
score. The prevalence of depression increased by age. The 10-year incidence of mild 
depression was 5%, increasing by age, and the 10-year incidence of moderate/severe 
depression was 1%, the same in the three age groups.  
Depression and UI 
In logistic regression analyses we found an association between depression at 
baseline and incidence of UI. For the whole study group the OR was 1.38 (1.13-1.69) 
for the association between having mild depression at baseline and developing any UI 
during the 10 year of follow-up. The OR was 2.09 (1.55-2.84) for the association 
between having moderate/severe depression at baseline and developing any UI during 
the follow-up. The highest OR was found for the association between 
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moderate/severe depression and incidence of the urgency UI component in the oldest 
age group. The associations were present for the stress as well as the urgency 
component, and for both mild and moderate/severe depression, as shown in Figure 8, 
but they did not reach statistical significance in all age groups.  
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Figure 8. The association between depression (by severity) at baseline an incident UI (by type) 
(Paper II). 
 
In the opposite direction, between UI at baseline and incidence of depression, we also 
found an association, but only significant regarding mild depression, here in all age 
groups. This is visualised in Figure 9. We found highest ORs for the urgency 
component of UI at baseline and developing mild depression in the youngest age 
group with OR 1.84 (1.11-3.03).  
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Figure 9. The association between UI (by type) at baseline and incident depression (by severity) 
(Paper II). 
Anxiety and UI  
For the whole study group, we found an association between anxiety at baseline and 
incidence of UI, with increasing ORs with increasing HADS-score, as shown in 
Figure 10. Compared with having normal anxiety score at baseline, the OR for 
incident UI was 1.45 (1.25-1.68) for mild anxiety and 1.65 (1.34-2.03) for 
moderate/severe anxiety at baseline. In the oldest age group, the associations were not 
significant. The highest OR was for the association between moderate/severe anxiety 
and incidence of urgency UI in the middle-aged group with OR 2.24 (1.49-3.37).  
In the opposite direction, between UI at baseline and incidence of anxiety, we found 
an association, but only statistically significant regarding mild anxiety. This 
association was significant for both stress and urgency component with highest OR 
for urgency component, OR 1.42 (1.14-1.77).  
For incidence of moderate/severe anxiety, the associations were not significant in the 
total group, but we found a strongly significant OR for urgency component at 
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Figure 10. The association between anxiety (by severity) at baseline and incident UI (by type) (Paper 
II). 
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Figure 11. The association between UI (by type) at baseline and incident anxiety (by severity) (Paper 
II). 
 
In conclusion, Paper II indicates that both depression and anxiety are predictors for 
the onset of UI. The study also shows a present, but weaker, association between UI 
and incident anxiety and depression.  
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10.3 Paper III 
The study group consisted of the 21.803 women who answered the UI questions on 
the questionnaire Q2 in HUNT3. This is the EPINCONT2 study group. The 
prevalence of any UI was 29%, 23% in the youngest group, and 32% among the 
oldest. In the total study group, 43% of the incontinent women had stress UI, 14% 
had urgency UI and 40% had mixed UI. 41% was classified as slight, 44% moderate 
and 12% had severe or very severe UI. 11% had mild anxiety, and of these 16% used 
an antidepressant drug. 6% had moderate/severe anxiety, and of these 30% used an 
antidepressant drug. 7% had mild depression, and of these 21% used an 
antidepressant drug. 2% had moderate/severe depression, and of these 35% used an 
antidepressant drug. In the total study group, 8% used an opioid analgesic, 5% used 
an anxiolytic drug, 10% used a hypnotic/sedative drug and 9% used an antidepressant 
drug. For all medication groups, the use increased by age.  
Having anxiety increased the prevalence of UI from 28% (normal HADS score) to 
35% (HADS-A 8-10) and 38% (HADS-A ≥11) (p<0.001). The UI prevalence 
increased to 41% in women with HADS- A ≥8 and concomitant use of 
antidepressants. Having depression increased the prevalence of UI from 28% (normal 
HADS score) to 39% (HADS-D 8-10) and 44% (HADS-D ≥11) (p<0.001). 
Concomitant use of antidepressants in women with HADS- D ≥8 did not increase the 
prevalence of UI additionally. 
Multiple logistic regression was performed using anxiety and depression as 
dependent variables. Adjusted for confounders and risk factors for UI except 
psychotropic drugs, any UI was associated with anxiety with OR 1.48 (1.36-1.60), 
and with depression with OR 1.58 (1.42-1.76). For both anxiety and depression, we 
found increasing ORs by increasing severity of UI and according to type, the 
strongest association was found for mixed UI.  
In descriptive analyses, using antidepressant drugs increased the prevalence of UI 
from 28% (no use) to 34% (low DDD), 39% (medium DDD) and 40% (high DDD). 
For opioid analgesics, other analgesics, antiparkinson drugs and hypnotics/sedatives 
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there was also an increase in the prevalence of UI with increasing DDD, but for 
antiepileptics, antipsychotics and anxiolytics there was no dose-dependent trend.  
After adjusting for psychotropic drugs, the OR for UI in persons with anxiety did not 
change compared to only adjusting for the other confounders and risk factors. 
However, medium and high volume (high DDD) of antidepressants and high volume 
of antiparkinson drugs were associated with UI. Consumption of high volume of 
anxiolytics and medium volume of hypnotics/sedatives were negatively associated 
with UI.  
In the logistic regression analyses with adjustments for psychotropic drugs, 
depression was associated with UI, OR 1.55 (1.39-1.73), compared to OR 1.58 (1.42-
1.76) when only adjusting for the other confounders and risk factors. Also, in these 
analyses, medium and high volume of antidepressants were associated with UI. High 
volumes of anxiolytics and medium volumes of hypnotics/sedatives were negatively 
associated.  
We analysed the possible impact of antidepressants and anxiolytics in stratified 
groups as well, one group with persons with depression and one group with persons 
with anxiety. In multiple logistic regression models, using antidepressants was not 
associated with UI, neither in the anxiety group nor in the depression group.  
In Paper III, UI was associated with anxiety, depression and use of antidepressants. 
Among women with depression, the prevalence of UI was similar among users of 
antidepressants and non-users. Among patients with anxiety, use of anxiolytic drugs 





In this chapter I will discuss the design and methods used in the thesis: Are they 
suitable to approach our aims? What are the limitations of the studies, and in what 
respect can they have affected the results? Can the studies contribute to the 
knowledge about causality regarding anxiety and depression versus UI? Secondly, I 
will discuss the results of the three papers in light of existing literature in the field.  
11.1 Main findings 
The main issue of the studies has been to investigate the relationship between UI and 
anxiety and UI and depression from an epidemiological perspective. The findings in 
this thesis can be summarised as follows:  
 A positive cross-sectional association between UI and anxiety as well as 
between UI and depression. The association was strongest for urgency and the 
mixed UI and for a severe degree of UI and anxiety/depression.  
 A positive association between depression and incident UI, and between 
anxiety and incident UI. A positive, but weaker, association between UI and 
incident anxiety, and also between UI and incident depression.  
 A positive cross-sectional association between use of antidepressants and UI. 
The associations between anxiety and UI and depression and UI were present 
irrespective of antidepressant use.  
11.2 Methodological considerations 
11.2.1 Design 
The designs in Paper I and Paper III are cross-sectional, and therefore descriptive in 
their approach to the research question. Cross-sectional studies can provide 
knowledge about associations between exposures (risk factors) and outcomes (disease 
or condition), but cannot give direct measures of the risk of the disease/condition. 
The results from cross-sectional studies often forms the basis for development of 
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hypotheses. The possibility of a causal relationship regarding associations found in 
cross-sectional studies must be handled with great awareness.  
An advantage of the population-based designs is the possibility to obtain information 
about many topics, from many participants at a low cost. The current topic of interest 
will be one of many, reducing the risk for over-reporting. For conditions associated 
with shame and taboo, like UI, it could also reduce under-reporting because it is 
easier to report such symptoms when it appears among other questions in a large 
questionnaire29. On the other hand, too many topics will result in a time-consuming 
questionnaire and thus a risk of lower response rate.  
After detecting cross-sectional associations between anxiety and UI, and depression 
and UI, the next research question was whether UI leads to anxiety and depression, or 
whether anxiety and depression leads to UI. Paper II has a longitudinal prospective 
design giving better basis for reasoning about the directions of the associations. A 10-
year follow-up is a long observation-time and could represent a limitation of Paper 
II. Especially anxiety and depression are fluctuating conditions. A depression can 
typically have a duration of six to twelve months, and may also be a recurrent 
condition138. UI may also be a transient condition, especially in the first years, and a 
proportion of women with UI move between UI types over time37.  
It is a goal in epidemiological research to present valid and precise estimates, whether 
it be of the frequency of a disease, or the effect of an exposure on the occurrence of a 
disease or a health problem. There are two main types of error in epidemiology, 
random and systematic error. Random error is linked to precision, and systematic 
error to validity151  
11.2.2 Precision 
An estimate is precise if there is little random error. Confidence intervals give 
information about the precision and also the strength of the association. Random error 
refers to unsystematic error, which can be measurement error and biological 
variation. By using validated measurement tools, the sampling error will be reduced. 
The UI questionnaire with a scale for severity and type, and the validated scale for 
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anxiety and depression scores in HADS, will increase the precision. Generally, 
random error can be reduced by increasing the sample size152. The studies in this 
thesis had large number of participants, especially Paper II and Paper III, giving 
relatively narrow confidence intervals. However, when analysing stratified groups, 
the number of participants in some groups became low, and the confidence intervals 
wider, indicating lower precision. The precision can also be reduced if the groups are 
unbalanced, with few participants in one exposure class. In Paper III, some of the 
drugs were used by very few participants, and when making groups by different 
volume of drug use, it was difficult to make equal sized groups to compare. In all 
three studies, the groups with moderate/severe anxiety and depression, and 
severe/very severe UI were relatively small. 
Small groups and precision are linked to the statistical power of the calculations.  
11.2.3 Validity 
Validity is linked to systematic error and is divided into internal and external validity. 
Regarding internal validity, an inference of the study is drawn about the source 
population. External validity (generalisability), concerns an inference drawn about 
the external, general population. The systematic error will not be influenced by 
changing the study size. The main types of systematic errors, which will be discussed 




Selection bias appear if the relation between exposure and disease/condition is 
different between those who participate in the study and those who were supposed to 
participate. The observed associations between an exposure and the disease/condition 
can then be caused by a mixture of factors which affect response rate, and factors 
which affect the disease/condition. Generally, selection bias is reduced by increasing 
study attendance. Selection bias can appear by several reasons, especially two of 
these may concern our studies and will be discussed here:  
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 If the study has a low response rate, or if the participating individuals are not 
representative for the population (self-selection). 
 If persons participating at baseline are not participating at follow-up (loss to 
follow-up). 
Self-selection 
Both in HUSK and HUNT, all women in a defined area were invited. HUSK and 
HUNT2 have relatively high participation rates of 70% and 74%, respectively. In 
HUNT the response rate dropped to 59% in HUNT3. This is part of a general trend 
where participation rates in population-based studies have declined during the last 
decades. Despite high participation rate in HUNT2, some age groups had quite low 
attendance, especially in the youngest and oldest groups. This could lead to 
uncertainty about UI among the oldest, because the prevalence increases by age, and 
because UI is associated with high morbidity and chronic disease51, 91, 97. Low 
attendance among the youngest could also lead to uncertainty. Young individuals not 
moving from the county have higher risk for UI because of higher parity.  
A study of non-responders in HUNT3 compared questionnaire data from HUNT3 
with data from other sources: a short questionnaire to nonparticipants, anonymous 
data on specific diagnoses, and prescribed medication extracted from general 
practices and Statistics Norway and the Norwegian Prescription Database143. The 
study showed lower participation among people who were young, unmarried and in 
lower socioeconomic groups. The risk of chronic disease like cardiovascular disease 
and diabetes, as well as morbidity, was higher among the nonparticipants. UI, 
musculoskeletal pain and headache were more common among participants in the 
study, compared to nonparticipants. The prevalence among non-responders was based 
on diagnoses in GP records. However, we know that there could be a threshold to 
mention UI to the doctor153, and questions in a population-based survey are much 
more sensitive to catch UI symptoms. The prevalence is thus expected to be higher in 
surveys. The prevalence of anxiety was higher, and the prevalence of depression was 
lower among participants compared to the prevalence of these conditions based on 
GP records. These prevalence estimates cannot be directly compared, but indicate 
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that depression is a more restricting factor for participation than anxiety143. Because 
the persons with severe depression may be underrepresented in the study, the 
estimated association between depression and UI may be biased. The main reasons 
for not participating in HUNT3 among the individuals younger than 70 years, was 
shortage of time or having moved out of the county. For individuals older than 70 
years, immobility due to disease or being under medical care were the main reasons. 
Women who were institutionalised were also excluded from the study file (60 
women). Especially among the oldest, this non-response may have contributed to a 
lower prevalence of UI, as we know that UI is associated with many somatic diseases 
such as diabetes, stroke and general functional impairment93, 96, 97, which may have 
been reasons for not participating.  
Drug use is higher among older people, and a lower participation rate among the 
oldest may also lead to uncertain estimates of drug use. If the healthiest young were 
moving out of the county for studying or working, a higher prevalence of UI in the 
study could be a consequence. HUNT3 had higher prevalence of UI among women 
<50 years, and also a lower participation rate, which in combination could indicate an 
overestimation of UI. If the healthiest young people move out of the county, the 
young people left in the county may use more drugs.  
Missing values may lead to selection bias. If a person has participated in the study, 
but have not answered the HADS questions or the questions about UI, the reason may 
be a high level of depression or anxiety leading to reluctance to answer questions 
about mental health. Regarding UI, some women may decline to answer because of 
shame related to their condition. In Paper I and Paper III, all women not defined as 
either continent or incontinent were excluded from the study group. However, there 
were missing values on type and severity. In Paper I missing values comprised 
approximately 8% in the analyses on type and 6% in the analyses on severity. In 
Paper III missing values were 0.6% in the analyses on type and 3.4% in the analyses 
on severity. In the logistic regression analyses in Paper I, missing cases due to 
missing values on one or more variables were approximately 8%. In Paper III, 
missing values in the logistic regression analyses were 6.5%.  
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Loss to follow-up 
This may be related to social conditions, health status, changing county of residence 
and death. In our material there are differences in UI variables among participants 
answering Q2 in both HUNT2 and HUNT3 and those answering Q2 only in HUNT2. 
This is shown in Table 8. The prevalence of UI was higher among those answering 
the UI questions at both occasions compared with those answering only HUNT2. 
Among women with UI, proportions with stress and urgency UI were highest in the 
group who answered both times, and mixed UI was most prevalent among those 
answering only HUNT2. Severe UI was most prevalent among those answering only 
HUNT2.  
 
Table 8. Prevalences of any UI, UI type and UI severity among participants who answered Q2 in 





Joined both HUNT2 and HUNT3 Joined only HUNT2 
 
N=16265 N= 2095 
N % N % 
UI 3857 23.7 441 21.1 
Type of UI     
 Stress 2093 54.7 216 49.0 
 Urgency 355 9.3 35 8.0 
 Mixed 1241 32.5 157 35.6 
Severity     
 Slight 1290 48.3 137 45.4 
 Moderate 1140 42.6 128 42.4 
 Severe 209 7.8 35 11.6 
 Very severe 34 1.3 2 0.7 
 
Information bias 
Information bias occurs when the information collected from the study participants is 
erroneous. If the variable is measured on a categorical scale and the error leads to a 
participant being placed in an incorrect category, it is called misclassification.  
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Misclassification can be either  
 differential misclassification or 
 non-differential misclassification 
Differential misclassification, recall bias 
With differential misclassification, the misclassification differs according to the value 
of other study variables, either that disease /condition classification of the participants 
relies on the exposure status, or vice versa154. This type of misclassification may bias 
the estimate in both directions, and may lead to both type 1 error and type 2 error. 
There will be differences in bias between the groups which are compared. Recall bias 
is a common type of differential misclassification. This happens if the exposure 
information is misclassified differentially for those with or without the 
disease/condition. In Paper II, persons without anxiety or depression at baseline may 
be underdiagnosed for UI more than persons with anxiety or depression. Persons with 
anxiety may be inclined to search health services and tell about their UI symptoms, 
and people with depression experience their condition-specific functional loss 
because of UI greater than persons without depression and could therefore report a 
more severe UI. Even if anxiety and depression did not lead to UI, depressed and 
anxious participants would appear to have a greater incidence of UI than those 
without anxiety and depression because of the greater likelihood that a case of UI 
would be diagnosed if the person had anxiety or depression, or remain undiagnosed in 
a person without anxiety or depression155. Reversely, there might be a tendency for 
women with UI to be more aware of anxiety symptoms related to especially 
unpredictable urgency symptoms. Recall bias could theoretically be avoided by 
conducting clinical examinations for UI as part of the study.  
Non-differential misclassification  
With non-differential misclassification, the misclassification is unrelated to other 
study variables. The classification of the disease/condition does not rely on the 
exposure status, and vice versa. The misclassification is at the same level in the 
groups which are compared. Non-differential misclassification can modify the 
exposure, outcome or confounders. Non-differential misclassification of the condition 
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takes place in every epidemiologic study to some extent. Non-differential 
misclassification impairs the possibility to reveal associations and can result in type 2 
errors.  
 Possible non-differential misclassification of anxiety and depression. 
Non-differential misclassification of a dichotomous exposure will normally bias the 
effect towards the null value. Non-differential misclassification between two 
categories of the exposure will make the effect estimates for the two categories 
converge towards one another154.  
A systematic review and assessment of Norwegian research using HADS was carried 
out by the Norwegian Knowledge Centre for Health Services in 2016. The central 
question is if HADS assess what we intend it to assess. HADS is generally one of the 
most used and well validated tools for measuring psychological distress148. One 
criticism against use of HADS has been that the scale measures general psychological 
distress, and not so well differentiates between anxiety and depression. One 
explanation could be that somatic symptoms (one of three main criteria for 
depression) are not included. The HADS was originally designed to measure anxiety 
and depression among patients with somatic illness, and the somatic symptoms were 
excluded from the questionnaire to avoid misinterpretation of the symptoms. This can 
also explain why studies with HADS miss to show gender differences concerning 
depression. 
Non-differential misclassification can also occur between two exposure categories, 
and the effect estimates for those two categories can then converge towards each 
other154. Anxiety and depression are often co-existing conditions, and a weak 
differentiation between anxiety and depression has been described as a weakness of 
HADS. This may be an explanation for converging estimates between anxiety and 
depression, especially seen in some of the analyses, e.g. in Table 3 in Paper III. The 
high co-existence between HADS-A and HADS-D are shown in Table 9.  
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Of 1871 individuals with high HADS-D score, 1141 individuals (61%) have 
coexisting high HADS-A score. Among individuals with high HADS-A score, 31% 
have coexisting high HADS-D score.  
 
Table 9. Coexistence of high HADS-A and HADS-D score in Paper III (Cross tabulation) Missing = 
314 individuals. 
 HADS-A<8 HADS-A ≥8 Total number 
HADS-D<8 17059 2559 19618 
HADS-D ≥8 730 1 141 1871 
Total number 17789 3700 21489 
  
 Possible non-differential misclassification of UI 
Our three studies are based on self-reported UI. The definition chosen is in 
accordance with the current recommendation from the ICS10. All women who 
reported any involuntary leakage of urine were considered to have UI. The sensitivity 
and specificity of the questionnaire have not been validated. The aim of the questions 
was to detect all the women who regarded themselves as leaking urine. A problem is 
that women have different thresholds for which frequency and amount of leakage is 
enough to define themselves as incontinent. Including questions about frequency and 
amount of leakage, is assumed to reduce this bias compared to only asking if the 
woman leaks urine. It is not likely that a woman will report UI if she has no leakage 
of urine. On the other hand, it is possible that our continent group contains women 
defining themselves as continent, but who would have been classified as incontinent 
of a physician. This can be due to an attitude that leakage is a normal condition. A 
problem connected to the questionnaire, is whether it should be an aim to detect all 
women with any leakage, also when the woman does not have any bother of the UI, 
or whether the aim should be to detect the women with bother of their UI. The last 
alternative could possibly bias the estimates towards lower levels.  
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25% of the participants in HUNT2 received, by a mistake, a wrong version of the 
questions about UI. The entry question “Do you have involuntary leakage of urine” 
was substituted by “Do you have involuntary leakage of urine at least twice per 
month?” The frequency question had three instead of four categories and the amount 
question had two instead of three categories. This error in the questionnaire could 
contribute to an underestimation of UI in HUNT2. An estimate of this was performed 
by ph.d. Marit Ebbesen. The prevalence loss was made assuming that the frequency 
distribution of the 25.0% women who got the default questionnaire on UI would have 
been equal to the 75% of the women who got the correct questionnaire. If this was the 
case, approximately 395 women was missed due to the error. This would have 
changed the prevalence of UI in HUNT2 to 26.1%, still lower than in HUNT3.  
 Possible non-differential misclassification of drug use.  
Drug use was defined as dispensed prescription over the last six months. We assume 
that dispensed prescription means that the person actually has taken the drug. The 
patient may choose not to use the drug, or the drug use can be discontinued without 
using the total amount of prescribed drug. This will give an overestimation of the real 
drug use. If the patient has purchased a prescribed drug several times, it seems more 
likely that she takes the drug. We therefore analysed for categories of medication 
users with one and two or more dispensed prescriptions, respectively, and for 
different DDD. In the final analyses we defined use of medication as ≥1 dispensed 
prescription to include all drug use, and also included individuals who had a short 
time using the drug. The estimates were quite similar for both definitions of drug use. 
Confounding 
Confounding can be defined as confusion of effects. The effects of the exposure are 
mixed with the effect of another variable. In contrast to selection and information 
bias, confounding can be handled during analyses if information about the variable is 
available. While bias creates an illusion of an association which is not true, 
confounding describes a true, but potentially misleading association when 
interpreting the results.   
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A confounder must, according to the following criteria by Rothmann154, be 
1. a risk factor or protective factor for the outcome 
2. associated with the exposure in the source population 
3. unaffected of the exposure or the outcome, especially not an intermediate step 
in the causal pathway from exposure to disease. 
A variable does not need to be a detected risk factor or protective factor for the 
outcome in the present study group to be a confounder. Knowledge about risk factors 
and causal factors independent of own data, must be used to consider potential 
confounders. In the relationships between anxiety and UI, and depression and UI, the 
following factors were considered to be confounders: 
 Age. Increasing age is a known risk factor for UI. Anxiety and depression have 
also different occurrence according to age. We adjusted for age in all three 
papers.  
 BMI. BMI is a risk factor for UI and is also associated with anxiety and 
depression. Increasing BMI could theoretically be a possible consequence of 
both depression, anxiety and UI trough inactivity, and it should therefore be 
discussed if BMI is a confounder or an intermediate step. We have chosen to 
adjust for BMI as a confounder because of the strong evidence of BMI as a 
risk factor for UI. We adjusted for BMI in all three papers.  
 Chronic somatic disease. Especially cardiac disease, diabetes, lung disease and 
stroke are associated with both depression, anxiety and UI, and were 
considered as confounders and adjusted for in all three papers. Theoretically, it 
cannot be ruled out that depression could lead to somatic illness, but we 
consider the opposite direction more important here, and therefore the third 
criterion to be a confounder was fulfilled. We adjusted for myocardial 
infarction, cerebral stroke, asthma and diabetes in Paper II and Paper III.  
 Low socioeconomic status. In some studies, high socioeconomic status is 
associated with higher prevalence of UI, but the studies are not conclusive. In 
Paper I, education level as a measure of socioeconomic status was regarded as 
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a possible confounder and was adjusted for. In Paper II and Paper III, we did 
not have access to data on socioeconomic status, and this is a possible 
weakness of the studies. 
 Smoking. Smoking is associated with anxiety and depression, and over a 
certain level also with UI. It is not likely that smoking is an intermediate step, 
and we regarded it to be a possible confounder. We adjusted for smoking in 
Paper I. 
 Nocturia. This is associated with UI, and in one study nocturia, but not UI, 
was associated with depression. We adjusted for nocturia in Paper I.  
 Parity. This is a strong risk factor for stress UI and is negatively associated 
with anxiety and depression. Even if anxiety, depression and UI theoretically 
could impact the parity variable, we have considered this impact to be less 
important, and have chosen to adjust for parity as a possible confounder in all 
three papers.  
 Chronic musculoskeletal pain. Different conditions of musculoskeletal pain, 
like fibromyalgia, is shown to be associated with UI, especially urgency UI. 
Depression and anxiety are often accompanied by somatic pain. Because pain 
is a possible consequence of depression and anxiety, and theoretically a 
possible intermediate factor, it should be considered if the third criteria for 
confounding is fulfilled. However, in Paper III we have regarded 
musculoskeletal pain as a confounder and adjusted for it in the analyses.  
Directed Acyclic Graphs (DAGs) is a useful tool to search for confounders156. Figure 
12 below gives an overview of the possible causal pathway from anxiety and 
depression to UI, and the confounders.  
In the analyses, confounding can be handled by stratification or multivariate linear 
statistical models as multiple linear regression and logistic regression. Stratification 
gives results which are easy to interpret and convey, but with less exact estimates 
than with for example multiple logistic regression analyses. In all three papers 
logistic regression was used to adjust for confounders.  
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In paper III, stratification was used in addition to multiple regression analyses to 
show the prevalence of UI among persons with anxiety and depression using and not 
using antidepressants and anxiolytics.  
 
 
Figure 12. Possible causal pathways in both directions between anxiety and UI and between 
depression and UI and possible confounders and associated factors. The factors with blue colour are 




Effect modification can occur when the size of an association between an exposure 
and an outcome varies by the level of a third factor157. In Paper III, psychotropic 
drugs can represent an effect modificator for the associations between anxiety and UI 
and between depression and UI. Especially antidepressants act in the same 
neurobiological system as the pathogenesis of anxiety and depression, and an 
interaction between the drug variables and the disease variables is possible. Effect 
modification can be identified by stratification or by multivariate statistical models. If 
the effect of an exposure on the outcome is equal in the different groups in the 
stratified analyses, the effect is called homogeneous. If the effects are different, they 
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are called heterogeneous. Interaction between two exposures can be either synergistic 
(the joint effect is higher than the sum of the effects of each exposure), or 
antagonistic (the joint effect is lower than the sum of the two effects). According to 
the treatment effect on anxiety and depression, it could be plausible that an 
antidepressant could modificate the association between anxiety/depression and UI 
negatively, not just strengthen it. Figure 13 below shows the possible influence of a 
psychotropic drug as an effect modificator on the association between 
anxiety/depression and UI, but also the possible direct line from the drug to UI.  
 
 
Figure 13. The possible effect modification of psychotropic drugs (especially antidepressants) on the 
association between anxiety/depression and UI. 
 
In Paper III we used both multivariate logistic regression and stratification to 
investigate for effect modification. There were no statistically significant differences 
in prevalence of UI among the participants with anxiety or depression using 
antidepressants compared to non-users.  
Mediation 
A mediator or an intermediate factor, is a variable representing a step in the chain on 
the pathway between the exposure and outcome157, as shown in figure 13 below. The 
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intermediate factor may partially, or completely, account for the association between 
the exposure and the outcome.  In the relations between anxiety and UI, and also 
between depression and UI, psychotropic drugs could be the intermediate step, which 
completely or partly could explain the association with UI. If a mediator is adjusted 
for, the estimated effect of the exposure will be only the direct effect, not mediated 
through (in this case) the drug.   
 
 
Figure 14. Psychotropic drugs as a possible mediator in a pathway from anxiety/depression and UI.  
 
External validity/Generalisability 
The external validity is good if the results of the study is valid for, or can be 
generalised for, a larger population outside the study population and independent of 
the time when the study has been performed. The external validity depends on the 
internal validity of the study. In addition, the results of other population-based studies 
may be different from ours if there are differences in age distribution, parity, obesity, 
socioeconomic conditions and other factors that influence UI and mental health. In 
HUSK, the age group is restricted to middle-aged women, and given the high 
response rate the results will be representative for women 40-44 years of age. 
However, representative study populations are not required to draw scientific 
inference, and results from a study with high internal validity can often be 
generalisable even if the study population is not representative. The associations 
between anxiety and UI, as well as depression and UI, are believed to have a 
biological basis, and if that is true, the results should be valid also for other 
populations. The former county of Nord-Trøndelag had no large cities and thus a 
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lower fraction of urban inhabitants. This could influence the prevalence of UI, though 
most likely to a small degree.  
Another factor which should be taken into consideration, is the time since the HUSK 
and HUNT studies were performed, and the possibility that the prevalence of the 
central variables and confounders may change over time have changed. A report from 
the Norwegian Institute for Public Health from 2018 found the prevalence of mental 
disorders to be stable, except increasing prevalence of depressive symptoms among 
young women. The openness about mental problems has increased over the last 
decades, and could contribute to less shame associated with them, and possibly a 
higher self-reported prevalence if the study had been repeated now. However, shame 
is most likely not a big obstacle to answer in a population-based survey with many 
topics.  
Among the confounders and risk factors for UI, BMI has been increasing since the 
studies were performed, and could therefore result in a higher prevalence of UI. 
Increasing BMI is also a possible factor contributing to the higher prevalence of UI 
found in HUNT3 compared with HUNT2. The treatment of UI has not changed to a 
considerable extent, and that will most likely not influence the prevalence and 
associations.   
In 2008 (HUNT3), 79 individuals (men and women) per 1000 inhabitants in Norway 
used an antidepressant drug. In 2018, 83 per 1000 used an antidepressant, according 
to data from NorPD (Reseptregisteret.no). This represents no significant increase 
(p=0.73 by chi-square). The majority of antidepressants purchased in Norway are still 
SSRIs. During the twelve years since the collection of Paper III data, there has not 
been launched any new SSRI in Norway. Regarding antipsychotics, some new drugs 
have been marketed. Outside hospital this includes sertindole, luasidone, asenapine 
and paliperidone. Our research results may not apply to these drugs.  
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11.3 Discussion of the results 
The prevalence of depression and anxiety among women with UI vary in different 
studies, and the main reasons are most likely various designs with disparate inclusion 
criteria as well as differences in definitions used for UI, anxiety and depression.  
In the studies we compare our main results with, the prevalence of UI vary from 3.2% 
(UI had to be diagnosed by a health professional)115 to 68% (questionnaire-based, by 
mail, UI defined as any leakage last 12 months)113. Among the population-based 
studies defining UI as any incontinence, most of the studies found prevalence of UI 
between 20 and 60%. The prevalence of UI in the papers in this thesis were 26.2% 
(Paper I, HUSK), 23.7% (Paper II, baseline HUNT2) and 29% (Paper III, 
HUNT3). The UI prevalence in HUSK is almost in line with the EPINCONT1 
(prevalence 25%)34. The baseline prevalence in Paper II (23.7%) differ from the UI 
prevalence in EPINCONT1 (25%), even if both studies are based on HUNT2-data. 
However, the selection is different, since our baseline population only includes the 
HUNT2-women who have also participated, and answered Q2, in HUNT3. This 
represents a selection bias (loss to follow-up), as already discussed. The prevalence in 
Paper III was higher than in HUNT2, as demonstrated in an earlier study from 
HUNT335. The reasons for this are not fully understood, but one reason may be a 
generally increasing BMI, which is a risk factor for UI.  
The prevalence of anxiety were 20%, 16% (baseline data) and 17% and the 
prevalence of depression were 8%, 9% and 9% in Paper I, Paper II and Paper III, 
respectively. These numbers are comparable with prevalence estimates from other 
large epidemiological studies136, 138. In the study of non-responders in HUNT3, the 
participants had higher prevalence of anxiety and lower prevalence of depression 
compared with the non-participants143.  
11.3.1 Anxiety and UI 
Cross-sectional associations (Paper I and Paper III) 
In Paper I, we found that among women 40-44 years, anxiety was positively 
associated with UI, with strongest association for severe UI, OR 2.30 (1.36-3.88) and 
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mixed, OR 2.05 (1.62-2.59) and urgency UI, OR 1.70 (1.14-2.56). However, an 
association was significant also for stress UI, OR 1.39 (1.14-1.69) and for less severe 
UI. In Paper III, this association was confirmed in a new sample with women 20 
years and older. The association was also here strongest for severe UI and mixed and 
urgency UI, and we observed an increasing strength of the association by increasing 
level of anxiety symptoms. Two other cross-sectional, population-based studies have 
found a similar association. In a large internet survey the prevalence of anxiety 
among women with stress or mixed UI combined with other UI was 50% and 49%, 
respectively113. In another cross-sectional study, self-reported history of anxiety and 
depression was associated with UI with OR 1.19105. In one cross-sectional study of 
women with UI, patients with mixed and urgency UI were much more likely to have 
panic disorder compared to those with stress UI57. There is a general lack of cross-
sectional studies with data on both type and severity of UI, and severity of anxiety, 
and our studies expand the cross-sectional evidence by better data on severity of all 
three conditions and type of UI57, 105, 113.  
Longitudinal associations (Paper II) 
In Paper II we found a positive longitudinal association between anxiety at baseline 
and 10-year incidence of UI. The association was present in all age groups, but was 
not statistically significant in the oldest group. The highest OR was seen for urgency 
component and for the highest symptom level of anxiety in the age group 40-54 
years, OR 2.24 (1.49-3.37). For the opposite direction, between having UI at baseline 
and 10-year incidence of anxiety, we only found a significant association among the 
oldest women with urgency component. For the whole study group, we found 
statistically significant associations between both urgency and stress UI at baseline 
and developing mild anxiety-symptoms.  
A longitudinal study with 1 year of follow-up, using HADS, also showed that anxiety 
predicts incident urgency UI, with OR 1.36.108. The same study also found an 
association between urgency UI and incident anxiety, with OR 1.56. In another 
longitudinal study, with 10-years follow-up, only UI with condition-specific 
functional loss, was associated with incident anxiety, with OR 2.55. In the same 
90 
 
study, agoraphobia and panic disorder (but not the whole group of any anxiety 
disorder) at baseline predicted incident UI with condition-specific functional loss119.  
11.3.2 Depression and UI 
Cross-sectional association (Paper I and Paper III) 
In both Paper I and Paper III, we found that depression was positively associated 
with UI. As for anxiety, the association was strongest for severe UI (OR 2.14 in 
Paper I and 2.04 in Paper III) and for mixed UI (OR 2.24 in Paper I and 1.85 in 
Paper III). The association was not statistically significant for urgency and stress 
types of UI in the multiple regression analyses in Paper I, but statistically significant 
for all types in Paper III. Several other cross-sectional studies have investigated this 
association during the last years. The definitions and variables available differ, but 
some of the studies use definitions quite similar to our studies, and have data on type 
and/or severity of UI 57, 61, 98, 105, 107, 113-115. In one cross-sectional study major 
depression was associated with moderate and severe UI with ORs 2.7 and 3.8, 
respectively61. In the same study women with depression in addition to UI had 
reduced QoL compared to women with only UI. In another cross-sectional study, 
mild/moderate and severe UI was associated with depression with ORs 1.41 and 1.82, 
respectively. One study among only women with UI found that urgency and mixed 
UI was associated with major depression with ORs 9.2 and 13.5, respectively, 
compared with stress UI. The same study also showed that depression impacts UI 
symptom reporting, incontinence-specific QoL, and functional status57. Most of the 
studies with information about type and severity, find the strongest association with 
mixed UI, urgency UI and severe UI61, 98, 107, 113, 117. As for anxiety, our studies expand 
the cross-sectional based knowledge by investigating for severities of both conditions 
and also type of UI.  
Longitudinal association (Paper II) 
In Paper II we found a positive longitudinal association between depression at 
baseline and 10-year incidence of UI. For the whole study group, the association was 
significant for both stress- and urgency components, and for mild and 
moderate/severe depression. The association did not reach statistical significance in 
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all age groups, most likely due to low number of participants in subgroups. The 
highest ORs were found for moderate/severe depression and for urgency component 
of UI. In the age group 55+ the OR was 3.1 for this association. For the whole study 
group, there were minimal differences between the ORs for urgency (1.5 and 2.3 for 
mild and moderate/severe depression, respectively) and for stress UI (1.5 and 2.2 for 
mild and moderate/severe depression, respectively). The opposite direction, from UI 
at baseline to incident depression, there were weaker associations, and only 
statistically significant for incident mild depression.  
Our findings correspond with another longitudinal study, which showed an 
association between major depression at baseline and a 6-year incidence of UI104, 
where major depression predicted the onset of UI with OR 1.46. In that study UI did 
not predict the onset of depression. Another study showed the same, but was limited 
by a long follow-up time of 18 years109. In a third 5-year follow-up study, depression 
at baseline was associated with the persistence of UI, but not incidence of UI158. Two 
other longitudinal studies also demonstrated a direction of the association from 
depression at baseline to UI at follow-up91, 118. One longitudinal study found that 
urgency UI predicted the onset of depression, but depression did not predict the onset 
of UI108. In a cohort study with several waves, women with depressive symptoms at 
one wave had 37% higher likelihood of reporting UI symptoms in the following 
survey118. 
Coexistence of anxiety and depression 
A combination of anxiety and depression symptoms are very common among patients 
with depression and anxiety159. In Paper I, 73% of the women with HADS-D ≥8 and 
31% of the women with HADS-A ≥8, had both HADS-A and HADS-D ≥8. In Paper 
III, 61% of respondents with HADS-D ≥8 also had HADS-A ≥8, and 31% of those 
with HADS≥8 also had co-existing HADS-D ≥8. This represents a characteristic of 
the conditions, but also reflects a problem with limited discrimination between 
anxiety and depression, known from validation studies of the HADS scale150. In 
Paper III, the strong correlation between anxiety and depression may be a major 
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reason for almost similar ORs for the associations between the drugs and UI in the 
analyses of anxiety and depression as independent factors.  
11.3.3 The impact of psychotropic drugs  
Several studies have shown an association between psychotropic drugs, especially 
antidepressants, and UI120, 123-125, 160. One study found a relative risk (RR) of 1.9 for 
UI and concomitant SSRI use124. Another study found a much higher prevalence of 
UI among antidepressant users (64%) than in the control group (33%)125. There has 
been some evidence for an association between benzodiazepines and UI132 and 
between antiepileptics and UI122. Parkinson´s disease can cause bladder dysfunction 
and UI161. There is a lack of studies on the effect of antiparkinson drugs on UI.  
The association between the use of psychotropics and UI has previously been 
investigated using data from HUNT3129. Mauseth et al found associations between 
use of SSRIs and UI and also between use of lamotrigine and UI, with ORs 1.52 and 
2.73, respectively, for two or more prescriptions during the last six months. They also 
found an association between one dispensed antipsychotic during the last six months 
and UI, with OR 1.91, but not statistically significant for two or more dispensed 
prescriptions. In addition, they did not find any significant associations between 
benzodiazepines or zopiclone/zolpidem and UI. To adjust for a possible confounding 
by indication, Mauseth et al adjusted for high HADS-D scores. That did not change 
the OR in their results considerably, leading to a conclusion that there is an 
independent association between the drug and UI.  
Like Mauseth et al, we found an independent association between antidepressants and 
UI. We expanded our analyses by grouping the drug users by DDD. We then found 
increasing ORs by increasing DDDs of antidepressants. Since our main focus was the 
associations between anxiety/depression and UI, we investigated the impact of drugs 
on these associations by making subgroups of women with depression or anxiety. An 
association between UI and antidepressant use was not present in these subgroups 
when the women with depression or anxiety using antidepressants were compared 
with women with these conditions not using antidepressants. The use of 
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antidepressants did not influence on the associations between anxiety and UI or 
between depression and UI. SSRIs make up the majority of the antidepressant drugs 
purchased in Norway. We examined antidepressants as a group and also SSRIs alone, 
and the results were almost similar. In the final analyses we used the whole group of 
antidepressants (N06A).   
Mauseth et al found an association between using lamotrigine and UI. Because of a 
low sample size in this subgroup, it was not possible to perform analyses regarding 
different DDDs. Another study found an association between non-benzodiazepine 
anticonvulsants and UI122. We did not find any associations between any DDD-group 
of antiepileptics and UI. Since the antiepileptic group of drugs are heterogeneous 
when it comes to mechanisms and actions at the molecular level, a much larger 
number of users would have been necessary to investigate each subgrup´s potential 
association with UI. 
Mauseth et al found an association between one prescription of antipsychotics last six 
months and UI, but this finding was not confirmed when analysed for two 
prescriptions. One other study found an association between atypical (second 
generation) antipsychotics and lower urinary tract symptoms (LUTS) 122. Since 
antipsychotics are both dopamine antagonists and alpha blockers, they may have a 
biological mechanism inducing UI120. Second-generation antipsychotics are also 
serotonin 5-HT2A receptor antagonists130. Antipsychotics could also hypothetically 
protect against UI through their anticholinergic effects120. Our study did not find any 
association between use of antipsychotics and UI, and we did not find any association 
with UI for any of the DDD-groups of antipsychotics.  
In addition to the association between antidepressants and UI, we also found an 
association with high DDD of antiparkinson drugs, but only statistically significant 
when adjusting for anxiety, not when adjusting for depression. There is a lack of 
studies investigating this association. 
Benzodiazepines and hypnotics with benzodiazepine-like mechanism and effect may 
theoretically cause relaxation of the urethral muscle and thus induce stress UI120. 
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High DDD of anxiolytic medication is in our study negatively associated with UI, 
both when adjusting for depression and anxiety. In the subgroups of women with 
anxiety and women with depression, UI was negatively associated with use of 
anxiolytics in the group of women with anxiety, but not among women with 
depression.  
In our study we classified the drug groups due to the ATC-groups. Three drug groups 
contain benzodiazepines: the anxiolytic group (N05BA), the hypnotic/sedative group 
(N05CD) and the antiepileptic group (N03AE01). According to statistics from 
Norwegian Institute of Public Health (NIPH) for 2018, the benzodiazepines (N05BA) 
made up 90% of the anxiolytic drug group (N05B), and the benzodiazepines in N05B 
made up for 80% of the total benzodiazepines purchased in 2018162. This could 
represent a limitation and may have resulted in a reduced strength of the associations 
found for this group. 
Changes in drug use since HUNT3 
In 2008, 79 individuals (men and women) per 1000 inhabitants in Norway used an 
antidepressant drug. In 2018, 83 per 1000 used an antidepressant, according to data 
from NorPD163. This represents only a small increase. The majority of antidepressants 
purchased in Norway is still SSRIs, in HUNT3 60%. According to NIPH, SSRIs 
made up 63% of the antidepressants purchased in 2018. The tricyclic antidepressants 
made up 3%. During the twelve years from the data in Paper III was collected, there 
has not been launched any new SSRI in Norway. Vortioxetine (Brintelix R), a 
serotonin reuptake inhibitor with receptor modulating effects, was launched in 2015. 
In the group of antipsychotics, some new drugs have been marketed. Outside hospital 
this include sertindole, luasidone, asenapine and paliperidone. The results may not be 
valid for these drugs. According to NIPH, the purchase of hypnotics/sedatives has 
been reduced with almost one third the last 10 years.  
The paradox of antidepressants and UI, both therapy and risk factor 
The influence of antidepressants on UI could theoretically follow several pathways 
and directions, summarised here:  
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1. As a risk factor for UI through the serotonergic and noradrenergic system, 
perhaps acting on 5-HT4 receptors in the bladder detrusor, causing detrusor 
overactivity and potentially urgency UI124, 160. 
 
2. As a treatment for stress UI. The serotonin- and noradrenaline reuptake 
inhibitor, the antidepressant duloxetine, has a documented effect as a treatment 
for stress UI, probably by increasing bladder capacity and increasing the 
activity in the striated urethral sphincter through increased levels of serotonin 
and noradrenaline in the pudendal presynaptic motor neuron71, 72.  
 
3. As a treatment for depression and anxiety, antidepressants could theoretically 
reduce a negative influence of depression and anxiety on UI. 
 
4. Using antidepressants may theoretically be regarded as an indicator of major 
depression. Thus, an association between antidepressants and UI may be a 
confounding by indication.  
The associations between anxiety and UI, and also between depression and UI, were 
in our studies not influenced by use of antidepressants or any other psychotropic 
drug, and the associations cannot be explained by effect modification or mediation. 
However, the antidepressant drugs act on the pathophysiological pathways for 
anxiety and depression and induce UI through the same neurohormonal signals as 
anxiety and depression.  
11.3.4 The models of aetiology  
Both psychological and biological mechanisms are possible explanations for the 
associations between anxiety and UI, as well as depression and UI3. Living with a 
condition associated with shame, loss of control, unpredictability and decreased 
quality of life, may lead to psychological stress, anxiety and depression symptoms, as 
explained earlier by the model of Perry et al108. The longitudinal studies, however, 
included Paper II in this thesis, give stronger epidemiologic support for depression 
and anxiety leading to UI than UI leading to depression and anxiety. The shared 
biological pathways, as outlined in the introduction of the thesis, gives support to a 
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causal thinking about the relationship between the conditions. The common 
neurobiological system with the serotonergic/noradrenergic transmitter systems, 
where the antidepressant drugs also interact, and a dysregulation of the hypothalamic-
pituitary-adrenal (HPA) axis, which is stress related, connects the conditions in a 
biological frame.  
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12. Future perspectives for clinical practice and 
research 
Some consequences for clinical practice and perspectives for future research may be 
suggested based on this thesis:  
 We found high prevalence of both anxiety and depression among women with 
UI. Other research has shown that condition-specific functional loss and 
decrease in quality of life are more pronounced in individuals with depression 
or anxiety in addition to UI, compared with individuals with UI alone. Despite 
the great influence on daily activity, many women never consult a doctor 
because of UI problems, and do not get available advice and treatment for the 
condition. And if they do, studies have shown that having a depression 
influences negatively the effect of treatment and is associated with persistence 
of UI. It is consequently of importance for clinicians to be aware of the co-
existence found in our studies to be able to offer to this group of patients 
necessary treatment.  
 The strongest associations are found between the urgency component of UI 
and anxiety/depression. The pathology of urgency and the OAB-complex is 
not fully understood. Only 50% of individuals with urgency have detrusor 
overactivity. More research and a better understanding of the pathology of the 
urgency complex could be important also for understanding the associations 
with anxiety and depression.  
 Even if the strongest associations in our studies are seen for mixed and 
urgency UI, there is also a considerable association between stress UI and 
anxiety/depression, in some age groups almost at the same level as 
mixed/urgency UI. Many previous studies focus only on urgency/OAB and 
anxiety/depression, but future research should expand the focus to include 
stress UI as well. 
 Use of antidepressants is an associated factor of UI and at the same time 




 We found an increased incidence of UI among women with depression and 
anxiety. Whether treating the depression and anxiety successfully could lead to 
decreasing incidence of UI, needs to be addressed.   
 A better discrimination between anxiety and depression and subgroups of 





The main objective of the thesis was to investigate the relationship between female 
UI and anxiety and depression in three general populations, both cross-sectionally 
and longitudinally. We also aimed to investigate the relationship in light of the use of 
psychotropic drugs. The studies have strengthened both the cross-sectional and 
longitudinal based evidence for an association between anxiety and UI and 
depression and UI, not influenced by psychotropic drug use.  
For both anxiety and depression, the associations were strongest for mixed, urgency 
and severe UI, but present also for stress UI and mild/moderate UI. While the focus 
in the literature often has been on urgency and overactive bladder, we also found a 
significant association between anxiety/depression and stress UI, even though the 
strongest associations also in our studies were seen with mixed and urgency UI. This 
could indicate that the reasons for the observed associations are multifactorial, since 
urgency and stress UI have different pathophysiological explanations. There are 
possible biological links to anxiety/depression in the pathophysiology of all three 
types of UI, and the increasing strength of the association by increasing severity of 
the conditions also supports the hypothesis of biological links between the conditions. 
The common biological pathways connecting the three conditions could be further 
explored, both in clinical and epidemiological designs. 
The longitudinal study showed that both anxiety and depression are predictors for 
development of UI. We also found significant, but weaker, associations between UI 
and incident anxiety and depression. In the group with anxiety and depression at 
baseline, the strongest associations with UI were seen for moderate and severe 
depression/anxiety. Based on the longitudinal data, clinicians should especially be 
aware of the risk of developing UI among women with severe depression.  
We found a high prevalence of UI among users of several psychotropic drugs, but 
after adjustments, only antidepressants were statistically significant associated with 
UI. However, the associations between anxiety and UI and between depression and 
UI were in our studies not influenced by use of psychotropic drugs. The fact that the 
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three conditions, and antidepressant drugs, share neurobiological pathways, can 
explain that both anxiety/depression and antidepressants independently are associated 
with UI.  
The load of evidence for the associations found in this thesis, and the knowledge 
about the implications for patients functioning, indicates a greater awareness in 
clinical practice. Even if the use of antidepressant drugs did not influence the 
associations between anxiety/depression and UI, we found an association between 
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Anxiety and Depression Associated With Urinary
Incontinence. A 10-year Follow-Up Study From the
Norwegian HUNT study (EPINCONT)
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Aims: Firstly, to investigate the association between depression, anxiety and urinary incontinence (UI) in a 10-year
longitudinal study of women. Secondly, to investigate the association between possible differences in the stress- and
urgency components of UI and different severities of depression and anxiety by age groups.Methods: In a longitudinal,
population-based survey study, the EPINCONT part of the HUNT study in Norway, we analyzed questionnaire data on
UI, depression and anxiety from 16,263 women from 20 years of age. Amultivariate logistic regressionmodel was used to
predict the odds of developing anxiety and depression among the women with and without UI at baseline and the odds of
developingUI among thewomenwith andwithout anxiety or depression at baseline.Results: Forwomenwith anyUI at
baseline we found an association with the incidence of depression and anxiety symptoms, OR 1.45 (1.23–1.72) and 1.26
(1.8–1.47) for mild depression and anxiety respectively. For women with depression or anxiety symptoms at baseline we
found an association with the incidence of any UI with OR 2.09 (1.55–2.83) and 1.65 (1.34–2.03) for moderate/severe
symptom-score for depression and anxiety, respectively, for the whole sample. Conclusions: In this study, both
depression and anxiety are shown to be risk factors for developing UI with a dose-dependent trend. UI is associated with
increased incidence of depression and anxiety. Neurourol. Urodynam. 36:322–328, 2017.
# 2015 The Authors. Neurourology and Urodynamics Published by Wiley Periodicals, Inc.
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INTRODUCTION
Several epidemiologic cross-sectional studies have linked
depression to urinary incontinence (UI) in women. The
association has been shown to be strongest for urgency and
mixed incontinence and for severe incontinence.1–7 An
association between anxiety and UI has also been found.5,8,9
Anxiety, depression and UI are all common health problems,
and a possible link between them is of great interest. Studies
have given conflicting answers on the question of whether it is
anxiety and depression that give a higher risk of incidence of UI
or UI that gives a higher risk of developing anxiety and
depression.8,10–12 In addition to the epidemiological substrate,
there are also biological and neurological explanation models
for both directions of the associations. Serotonergic pathways
and the sympathetic nerve system are involved in both UI,
anxiety, and depression.10,13–15
Longitudinal studies are necessary to better understand the
underlying causes and sequences of the observed associations
in the cross-sectional studies. With data from the large
Norwegian EPINCONT study, based on the Nord-Trøndelag
Health Survey 2 and 3 (HUNT2 and HUNT3), the main objective
of the present study was to investigate the associations
between depression, anxiety and UI in women in a prospective
10-year follow-up study.
MATERIALS AND METHODS
The Nord-Trøndelag health study (HUNT) was a large
population-based survey, which all persons aged 20 years
and older in the county of Nord-Trøndelag were invited to
participate in. HUNT3 (2006–08) included the same questions
asHUNT2 (1995–97) on the topics of UI, anxiety and depression.
47,177 women were invited to participate in HUNT2, and
47,415 in HUNT3. The invitation included questionnaire one
(Q1), which the participants were asked to bring to a screening
station where several clinical examinations were done and
blood samples were drawn. The women who met inclusion
criteria at the screening station received questionnaire two
(Q2). In HUNT2, the questions about anxiety and depression
were inQ1 and the questions aboutUIwere inQ2. InHUNT3 the
questions in both of these areas were in Q2. 34,653 (73.5%)
answered Q1 in HUNT2. 80.8% of those who answered Q1
answered the incontinence part of the study in Q2 in HUNT2.
27,761 (58.7%) of those invited answered Q1and 21,804
answered Q2 in HUNT3. 16,253 women answered Q1 and Q2
in HUNT2 and Q2 in HUNT3, and our study was a longitudinal
survey of the women in this subgroup. Figure 1 is a
vizualization of the study-population of the women who
were invited to the HUNT-study until theywere included in the
study-group. For the analyses we used three age groups: 19–39
years, 40–54 years and 55 years and older.
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Urinary Incontinence Variables (EPINCONT Study)
The incontinence part of the questionnaire is known as
the EPINCONT study (Epidemiology of Urinary Incontinence
in Nord-Trøndelag).16 For analyses UI was defined as any
leakage of urine.17 If the answer to the entry question of
whether she had experienced leakage was yes, the woman
was asked to answer more specific questions about the
leakage of urine; how often (four levels), how much (three
levels) and in which situations she experienced the leakage. A
stress UI component was defined when the woman experi-
enced loss of urine when coughing, laughing, sneezing, or
making an effort. An urgency UI component was defined
when she experienced urgency to void. The incontinence was
classified as stress incontinence if she answered ‘‘yes’’ on the
stress component question and urgency incontinence if she
answered ‘‘yes’’ on the urgency component question. Mixed
UI was defined if she answered ‘‘yes’’ on both these questions.
Only stress and urgency UI components were used in the
analyses.
Anxiety and Depression Variables
Anxiety and depression was measured by the Hospital
Anxiety and Depression Scale (HADS).18,19 This is a self-
administered questionnaire consisting of 14 items, seven for
anxiety (HADS-A) and seven for depression (HADS-D). Each
item has four possible answers and is scored on a Likert
scale from 0 to 3. The item scores are added, giving subscales
from 0 (minimum symptom level) to 21 (maximum symptom
level).
The developers of the scale have recommended three cut-off
scores:mild (8–10), moderate (11–14), or severe (15–21) anxiety
or depression.18,20 Here the moderate and severe groups
(scores>11) are combined into a common ‘‘ moderate/severe’’
group. Data on the validity of HADS have been published.20–22
Statistical Analyses
All statistical analyses were performed using SPSS version
22.0. Statistical significance was accepted at a 5% level.
Logistic regression analyses were performed to investigate
the associations between anxiety and depression and UI.
Associations are shown as odds ratios (ORs) with 95%
confidence intervals (CIs). In the regression model we
adjusted for age, body mass index, parity, myocardial
infarction, cerebral stroke, asthma, and diabetes. Age was
used as a continuous variable, the other adjustment variables
were used as categorical variables.
To see if anxiety and depression could predict the onset of
UI during follow-up we first excluded women who had UI at
baseline. Then we made two groups of cases; those with
HADS-score 8–10 and those with HADS-score 11 at baseline.
Women with HADS< 8 were controls. Conversely, to see if UI
could predict the onset of anxiety and depression during
follow-up, we first excluded those women who had anxiety or
depression at baseline. Women with UI at baseline were now
the cases and the women without UI at baseline were the
controls.
Ethics
Approvals for the HUNT study were obtained from the
Regional and National ethics review board and from the
Norwegian Data Inspectorate.
RESULTS
Sixteen thousand two hundred and fifty-three women
answered the UI-questions and the questions concerning
anxiety and depression in both HUNT2 and HUNT3 and could
thus be included in the follow-up study.
Table I shows the characteristics of the included women at
baseline regarding UI, anxiety, depression, and the adjustment
variables used, in total and by the three age groups. Mean age
was 47 years, andmean number of childrenwas 2.1. Prevalence
of UI was 23.7%, highest among the middle-aged, and lowest
among the youngest. One in five reported a stress UI
component, again highest among the middle-aged, and least
in the youngest group. One in ten reported an urgency UI
component, this was highest among the eldest.
About one in ten had mild and about one in twenty had
moderate/severe levels of anxiety, with small differences
between age groups. Depression, however, showed increasing
prevalence by increasing age. The incidence of UI during the 10-
year follow-up period was 18.7%, highest for the stress UI
component and for the youngest age group. The 10-year
incidence was 7.6% and 2.5% for mild and moderate/severe
levels of anxiety, respectively, and 5.2% and 1.2% for mild and
moderate/severe levels of depression, respectively (Table I). The
incidences of anxiety and depression showed less variance by
age groups than for UI.
UI and Depression
Table II presents adjusted analyses from logistic regression
for the associations (ORs) between depression and the
incidence of any UI, a urgency UI component and a stress
UI component. We found a highly significant association
between developing UI and high depression score at baseline.
The associations are present in all three age groups and for
both urgency UI and stress UI components, but the
associations did not always reach statistical significance.
Fig. 1. Visualization of the study-population of women who were invited to
the HUNT-study until they were included in the study-group.
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TABLE II. Adjusted Analyses From Logistic Regression for the Associations Between Depression and the Incidence of Any UI, a Urgency UI Component and a
Stress UI Component









Number of women (N) OR 95%CI OR 95%CI OR 95%CI OR 95%CI
Incident any UI (N¼ 2,054)
HADS-D < 8 (N¼ 14,613) Ref. Ref. Ref. Ref.
HADS-D 8–10 (N¼ 1,057 1.62 1.11–2.36 1.30 0.92–1.83 1.33 0.93–1.89 1.38 1.13–1.69
HADS-D 11(N¼ 383) 1.84 0.99–3.40 2.07 1.28–3.34 2.54 1.51–4.27 2.09 1.55–2.84
Incident urgency UI component (N¼ 997)
HADS-D< 8 (N¼ 14,613) Ref. Ref. Ref. Ref.
HADS-D 8–10 (N¼ 1,057 1.60 0.95–2.69 1.27 0.80–2.02 1.66 1.11–2.50 1.50 1.15–1.94
HADS-D  11 (N¼ 383) 1.99 0.86–4.57 1.98 1.05–3.73 3.10 1.71–5.60 2.30 1.57–3.36
Incident stress UI component (N¼ 1,641)
HADS-D < 8 (N¼ 4,613) Ref. Ref. Ref. Ref.
HADS-D 8–10 (N¼ 1,057) 1.64 1.11–2.44 1.27 0.86–1.86 1.60 1.10–2.33 1.46 1.17–1.83
HADS-D 11 (N¼ 383) 1.83 0.95–3.52 2.56 1.57–4.18 2.21 1.21–4.03 2.22 1.60–3.08
Results are given as odds ratios (OR) with 95% confidence intervals (CI). The analyses are adjusted for age, body mass index, parity, myocardial infarction,
cerebral stroke, asthma, and diabetes.
TABLE I. Characteristics of the Included Women at Baseline, Shown in Total and by Three Age Groups









Number of women (N) N % N % N % N %
Urinary incontinence (UI)
Any UI 889 17.3 1753 27.7 1213 25.4 3856 23.7
Stress UI component 744 14.5 1567 24.8 1022 21.4 3334 20.5
Urgency UI component 334 6.5 645 10.2 617 12.9 1596 9.8
Mixed UI 252 4.9 533 8.5 533 11.2 1321 8.1
Other/unclassified 153 3.0 229 3.6 280 5.9 662 4.1
Anxiety
HADS-A 8–11 546 10.6 749 11.8 524 11.0 1821 11.2
HADS-A 11 265 5.1 388 6.1 252 5.3 905 5.6
Depression
HADS-D 8–11 202 3.9 434 6.9 421 8.8 1057 6.5
HADS-D 11 72 1.4 167 2.6 144 3.0 383 2.4
Parity
None 1037 20.1 301 4.8 321 6.7 1661 10.2
1 880 17.1 499 7.9 312 6.5 1691 10.4
2 1900 36.9 2626 41.5 1169 24.5 5695 35.0
 3 1303 25.3 2880 45.5 2929 61.3 7114 44.0
Body mass index
< 18.5 79 1.5 28 0.4 18 0.4 125 0.8
18.5–24.9 2978 57.9 2925 46.2 1434 30.0 7337 45.1
25.0–29.9 1523 29.6 2426 38.3 2208 46.2 6157 37.9
> 29.9 544 10.6 948 15.0 1106 23.1 2598 16.0
Incidence of UI
Any UI 895 22.2 665 15.9 492 17.9 2054 18.7
Stress UI component 753 19.4 528 13.0 358 13.7 1641 15.5
Urgency UI component 369 10.5 333 8.6 294 11.5 997 10.1
Incidence of anxiety
HADS-A 8–10 330 7.9 363 7.3 272 7.6 965 7.6
HADS-A 11 119 3.0 125 2.7 57 1.7 301 2.5
Incidence of depression
HADS-D 8–10 191 4.0 248 4.5 309 7.8 749 5.2
HADS-D 11 51 1.1 57 1.1 49 1.3 158 1.2
Asthma 403 7.8 453 7.2 374 7.8 1232 7.6
Myocardial infarction 2 0 11 0.2 76 1.6 89 0.5
Cerebral stroke 9 0.2 25 0.4 77 1.6 111 0.7
Diabetes 22 0.4 65 1.0 130 2.7 217 1.3
Results are given as N and percentages.
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The ORs were higher for HADS-D score 11 and over than for
HADS-D scores 8–10 for all age groups and for both types of
UI, thus indicating a ‘‘dose-dependent’’ trend. The highest OR
(3.07) was found for urgency UI and moderate/severe
depression in the oldest age group.
Table III shows adjusted analyses from logistic regression for
the associations (ORs) between anyUI, a urgency UI component,
and a stress UI component, and the incidence of mild and
moderate/severe levels of depression. We found that any UI, a
urgency UI component, and a stress UI component at baseline,
were all statistically significantly associated with the incidence
of MILD depression (HADS 8–10) in all age groups with the
highest ORs in the youngest age group. We also saw an
association with moderate/severe depression score, but these
results weremostly not significant. There were generally higher
ORs for a urgency UI component than for a stress UI component.
UI and Anxiety
Table IV shows adjusted analyses from logistic regression for
the associations (ORs) between anxiety and the incidence of
any UI, and urgency UI and stress UI components. As for
depression, we found a highly statistically significant associa-
tion between developing any UI and the two UI components
and having a high anxiety score at baseline. However, the
associations were not statistically significant in the oldest age
group for any UI category. The ORs were higher for HADS-A
score 11 and over than forHADS-A scores 8–10 for all age groups
and for both types of UI, thus indicating a ‘‘dose-dependent’’
trend. The highest OR (2.25) was found for a urgency UI
component and moderate/severe anxiety in the middle age
group.
Table V shows adjusted analyses from logistic regression for
the associations (ORs) between any UI, a urgency UI compo-
nent, and a stress UI component, and the incidence of mild and
moderate/severe levels of anxiety.
We found statistically significant associations between
the incidence of MILD anxiety (HADS-A 81–10) in the total
sample for women with any UI and stress and urgency UI
components at baseline. For the different age subgroups the
ORs for anxiety were generally lower than for depression. The
incidence of moderate/severe levels of anxiety was statisti-
cally significant only for a urgency UI component in the older
age group.
TABLE IV. Adjusted Analyses From Logistic Regression for the Associations Between Anxiety and the Incidence of Any UI, a Urgency UI Component and a
Stress UI Component









Number of women (N) OR 95%CI OR 95%CI OR 95%CI OR 95%CI
Incident any UI (N¼ 2,054)
HADS-A< 8 (N¼ 13,161) Ref. Ref. Ref. Ref.
HADS-A 8–10 (N¼ 1,821) 1.43 1.12–1.88 1.73 1.13–1.99 1.17 0.84–1.61 1.45 1.25–1.68
HADS-A 11(N¼ 905) 1.78 1.28–2.47 1.79 1.28–3.33 1.36 0.86–2.15 1.65 1.34–2.03
Incident urgency UI component (N¼ 997)
HADS-A< 8 (N¼ 13,161) Ref. Ref. Ref.
HADS-A 8–10 (N¼ 1,821) 1.53 1.10–2.14 1.81 1.31–2.51 1.30 0.88–1.92 1.54 1.26–1.88
HADS-A 11 (N¼905) 2.11 1.37–3.23 2.24 1.49–3.37 1.58 0.92–2.72 1.98 1.53–2.57
Incident stress UI component (N¼ 1,641)
HADS-A< 8 (N¼ 13,161) Ref. Ref. Ref. Ref.
HADS-A 8–10 (N¼ 1,821) 1.43 1.12–1.81 1.73 1.32–2.27 1.21 0.84–1.75 1.50 1.27–1.76
HADS-A 11 (N¼ 905) 1.78 1.28–2.49 1.96 1.38–2.79 1.47 0.89–2.44 1.75 1.41–2.19
Results are given as odds ratios (OR) with 95% confidence intervals (CI). The analyses are adjusted for age, body mass index, parity, myocardial infarction,
cerebral stroke, asthma and diabetes.
TABLE III. Adjusted Analyses From Logistic Regression for the Associations Between Any UI, Urgency and Stress UI Components and the Incidence of Mild
and Moderate/Severe Depression









Number of women (N) OR 95%CI OR 95%CI OR 95%CI OR 95%CI
Incident HADS-D 8–10 (N¼ 749)
Continence (N¼ 11,683) Ref. Ref. Ref. Ref.
Any UI (N¼ 3,856) 1.66 1.17–2.35 1.46 1.11–1.92 1.44 1.10–1.89 1.45 1.23–1.72
Urgency UI component (N¼ 1,596) 1.84 1.11–3.03 1.63 1.11–2.40 1.69 1.20–2.36 1.65 1.32–2.07
Stress UI component (N¼ 3,334) 1.66 1.15–2.41 1.45 1.09–1.94 1.45 1.08–1.93 1.45 1.21–1.73
Incident HADS-D 11 (N¼ 158)
Continence (N¼ 11,683) Ref. Ref.
Any UI (N¼ 3,856) 1.37 0.69–2.73 1.70 1.98–2.95 1.15 0.58–2.29 1.43 1.00-2.06
Urgency UI component (N¼ 1,596) 2.21 0.92–5.33 0.85 0.30–2.41 1.85 0.85–4.03 1.52 0.92–2.50
Stress UI component (N¼ 3,334) 1.19 0.54–2.60 1.85 1.05–3.26 1.03 0.48–2.22 1.40 0.95–2.06
Results are given as odds ratios (OR) with 95% confidence intervals (CI). The analyses are adjusted for age, body mass index, parity, myocardial infarction,
cerebral stroke, asthma and diabetes.
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Unadjusted results from logistic regression analyses for
Tables I–V are not shown due to very similar results and trends.
DISCUSSION
This study indicates that both depression and anxiety are
predictors for the onset of UI and that UI is a predictor for the
onset of both anxiety and depression in women from 20 years
of age. We investigated the association between the degree of
depression and anxiety score, the UI component, and age
group. With both depression and anxiety at baseline, the
association with the onset of UI is stronger with a higher
HADS-score. The highest ORs are found in the groups with
HADS-D and HADS-A11 at baseline developing a urgency UI
component, in the eldest group for depression score and in the
middle-aged group for anxiety. The association between
urinary incontinence at baseline and the incidence of anxiety
and depression is strongest with HADS 8–10 in the total
sample, and we see the highest ORs for a urgency UI
component.
In a large prospective study like ours the design indicates
more certain evidence than can be found in a cross-sectional
study, but the associations found are not proof of causality.
The strengths of the study include a population-based design
with a large sample size and a good response rate; as far as we
know one of the largest studies investigating this topic. All
adult women 20 years and older were invited to participate,
and results from the study give representative knowledge
about the entire adult female population. Most other studies
focus on elderly women only, or a more narrow age-group.
However, in our study we experienced problems with low
statistical power for small subgroups. We used validated scales
for UI, anxiety and depression and the HADS and UI questions
were part of a larger survey, which reduces the possibility of
both under- and over-reporting. The questionnaire with
symptom-based questions about UI is based on the definition
of the International Continence Society.17 The incidence of
urinary incontinence in the EPINCONT study is in the lower
range compared with incidences reported in other longitudinal
studies. This is discussed in another study from HUNT.23 The
HADS is widely used in population-based studies. A cut-off
score of eight on each subscale has been found to screen
adequately for case-level depression and anxiety according to
DSM-III/IV and ICD-8/9 diagnostic criteria.22 A cut-off of 11 is
also used to classify severity level.
Another strength of the study the ability to investigate the
associations between the two different components of UI, the
two severities of depression- and anxiety scores and the three
groups of age.
The limitations of the study include the potentially lower
participation in a mail-survey of the persons with the most
symptoms, especially very depressed women. 73.5% and 58.5%
of the invited personsmet the inclusion criteria at the screening
station in HUNT2 and HUNT3, respectively, and almost 80% of
those who received the questionnaire answered the EPINCONT
part. Even though the answering percentage is high, the lower
percentage of persons meeting inclusion criteria at the
screening station represents a possible selection bias. HADS
is not a diagnostic instrument even if it is a good tool to assess
symptom load.21 We know that there are possible shared
biological underliers for depression, anxiety and UI, and the
lack of information about psychiatric medication and medical
treatment of UI, represents a limitation. Lack of information
about functional loss could also be a limitation aswe know that
this is important in both UI and anxiety and depression. One
study found that only UIwith functional loss was a predictor of
anxiety after adjustments.24 The broad definition of UI used in
our studywill includemanywomenwith no bother or only low
bother due to their UI.
Depression and Anxiety at Baseline and Incident UI
We found a significant association between depression at
baseline and development of UI. The association was strongest
for the women with the highest HADS-score. This corresponds
well with the results of a 6-year longitudinal study10 where
they found an OR of 1.46 (1.08–1.97) of developing UI in the
group with major depression at baseline. That study was
limited by only including patients with a major depression
score and apopulation of only olderwomen. Our results are also
supported by an earlier study25 which found that women with
depression at baseline had a relative risk (RR) of 1.6 (1.2–2.0) of
being diagnosed with UI over a 9-year follow-up. That study
was limited to individuals with medical record diagnoses. In a
recent prospective study among young women, the women
with depressive symptoms or a history of depression were
more likely to develop UI symptoms during follow-up.26 A one-
year longitudinal study found that the incidence of cases of
urgency UI were predicted by anxiety at baseline, but not
depression.8 In a 5 year follow-up study investigating 475
TABLE V. Adjusted Analyses From Logistic Regression for the Associations Between Any UI, Urgency and Stress UI Components and the Incidence of Mild
and Moderate/Severe Anxiety









Number of women (N) OR 95%CI OR 95%CI OR 95%CI OR 95%CI
Incident HADS-A 8–10 (N¼ 965)
Continence (N¼ 11,683) Ref. Ref. Ref.
Any UI (N¼ 3,856) 1.24 0.92–1.67 1.33 1.05–1.69 1.24 0.93–1.66 1.26 1.08–1.47
Urgency UI component (N¼1,596) 1.23 0.77–1.96 1.38 0.97–1.95 1.61 1.13–2.30 1.42 1.14–1.77
Stress UI component (N¼ 3,334) 1.25 0.90–1.72 1.30 1.01–1.67 1.25 0.92–1.71 1.25 1.06–1.47
Incident HADS-A 11 (N¼ 158)
Continence (N¼ 11,683) Ref.
Any UI (N¼ 3,856) 1.37 0.85–2.20 0.93 0.61–1.42 1.30 0.71–2.41 1.12 0.84–1.48
Urgency UI component (N¼1,596) 1.84 0.96–3.53 0.64 0.29–1.39 2.55 1.32–4.94 1.33 0.90–1.96
Stress UI component (N¼ 3,334) 1.41 0.85–2.33 0.90 0.57–1.42 1.57 0.85–2.91 1.15 0.86–1.55
Results are given as odds ratios (OR) with 95% confidence intervals (CI). The analyses are adjusted for age, body mass index, parity, myocardial infarction,
cerebral stroke, asthma and diabetes.
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womenwithUI at baseline, the persistence ofUIwas associated
with depression symptoms. They also found that treatment of
UI did not affect the association.11 In a 18-year follow-up study
with a median follow-up of 12 years depressive symptoms
were associated with incidence of UI with a hazard ratio of 1.31
(1.09–1.56).12
There are fewer studies on anxiety as a risk factor for UI. In
one longitudinal study anxiety was both a risk factor and a
consequence of urgency incontinence.8 A longitudinal study
found a strong association between anxiety at baseline and UI
with incontinence-related functional loss. They did not find any
significant association with UI without function loss.25 A later
longitudinal study investigating the relationship between
anxiety disorder and UI, also found that persons with anxiety
at baseline had a significantly higher incidence of UI, but this
was only significant with condition-specific functional loss.27
In the present study, among those with anxiety at baseline
and an incidence of UI, there were higher ORs for developing a
urgency UI component compared to a stress UI component in
all age groups. This is similar to the strong association between
urgency UI and anxiety found in a cross-sectional study5 and a
longitudinal study.8
UI at Baseline and Incident Anxiety and Depression
We found an association between UI at baseline and the
incidence of depression, only significantwith amild depression
score (HADS 8–10), with the highest ORs for a urgency UI
component at baseline. One earlier study did not find this
association,10 but that study only investigated major depres-
sion, and thus might not catch the association with mild
depression. In another one year longitudinal study using HADS
and data on both stress and urgency UI at baseline, depression
was found to predict urgency UI, but not stress UI.8
Our study found an association between UI at baseline and
the onset of anxiety, alsomost significant for amildHADS-score
and with highest ORs for a urgency UI component in most age
groups. This corresponds with two other studies,8,27 but in
the latter the association was only significant when the UI was
accompanied with a condition-specific functional loss.27
No other study we know of has been able to differentiate
between severities of depression and anxiety in association
with UI. Our study indicates a ‘‘dose-response’’ effect in the
association between depression or anxiety at baseline and the
development UI. With UI at baseline the association with
the incidence of depression and anxiety is only significant with
a mild symptom score, but this could be a result of low
statistical power in the small subgroup.
Possible Mechanisms
Leakage represents loss of control, and the less predictable
the UI, themore disturbing it is for the person, which could lead
to helplessness, anxiety and depression.28 Dysfunctional beliefs
and automatic negative thoughts about social stigma could
lead to increased functional loss with increased anxiety
symptoms and sadness. Cognitive barriers may also decrease
a person’s benefit from treatment for UI.28 In one longitudinal
study depression at baselinewas associatedwith persistence of
UI.11 UI also often remains underdiagnosed because many
patients never consult a doctor for their problem.29 Depression
and anxiety could also contribute to a delay in help-seeking.
Having a chronic illness also in itself represents a burden that
could lead to sadness and depression. In addition, UI can lead to
social isolation and fewer outside activities, which may
contribute to depression.10,13
Serotonergic pathways are linked to both the regulation of
voiding function and depression. Serotonin inhibits the
micturition reflex pathway and facilitates the closure of the
urethral sphincter. The level of serotonin is low in clinically
depressed persons. Duloxetine is a serotonin and noradrenalin
reuptake inhibitor and has been shown to improve inconti-
nence and quality of life in patients with stress UI.15,30,31
CONCLUSIONS
In this large 10-year follow-up study of 16,253 women aged
20 years and older we found that women with depression or
anxiety at baseline were about 50% more likely to develop UI
during follow-up than other women, increasing with a high
HADS-score. UI at baseline was associated with developing
both anxiety and depression, with highest ORs for a mild to
moderate depression-score. We know that women with
comorbid depression or anxiety and UI have an increased
symptom burden from their conditions compared to women
with only one of the conditions, therefore it is important to be
aware of the association between the conditions, both as a
public-health priority and for physicians in their management
of such patients.
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This is a notice with regard to a paper that we published in Neurourology and Urodynamics in 2015/2017.1
During our further scientific work in this field, we have discovered an error in Table 1 of that paper. It concerns
the first part of the Table, about Mixed UI and Other/unclassified UI. All the numbers in these two lines are wrong.
Below we show the printed version and the correct numbers (in red):
Printed version
Age at inclusion, y 19‐39 40‐54 55+ All
Number of women (N) N= 5147 N= 6330 N= 4780 N= 16 263
N % N % N % N %
Urinary incontinence (UI)
Any UI 889 17.3 1753 27.7 1213 25.4 3856 23.7
Stress UI component 744 14.5 1567 24.8 1022 21.4 3334 20.5
Urgency UI component 334 6.5 645 10.2 617 12.9 1596 9.8
Mixed UI 252 4.9 533 8.5 533 11.2 1321 8.1
Other/unclassified 153 3.0 229 3.6 280 5.9 662 4.1
Correct version
Age at inclusion, y








N = 16 263
N % N % N % N %
Urinary incontinence (UI)
Any UI 889 17.3 1753 27.7 1213 25.4 3856 23.7
Stress UI component 744 14.5 1567 24.8 1022 21.4 3334 20.5
Urgency UI component 334 6.5 645 10.2 617 12.9 1596 9.8
Mixed UI 247 4.8 513 8.1 481 10.1 1241 7.6
Other/unclassified 51 1.0 48 0.8 34 0.7 133 0.8
For Mixed UI the errors are small and of no practical impact. For Other/unclassified the changes in numbers (N) are
significant and the changes in percentages (%) are larger. However, the group of Other/unclassified is now much
smaller and of much lower impact, and was anyway not an important focus of the paper and is not given any special
emphasis further in the paper. In addition, the variables with wrong numbers are not used in further analyses,
especially not in the logistic regression analyses, and do therefore not influence the main results in the study.
However, as we recently discovered this fact, we feel obliged to inform you as Editor‐In‐Chief about the errors. We ask
for your decision on the matter, and whether an Errata should be printed in the Journal.
Sincerely yours
Gunhild Felde, Marit Ebbesen, and Steinar Hunskaar
The authors
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